,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,77,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
30,79,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
31,81,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
32,83,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
33,85,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
34,87,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
35,89,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
36,91,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
37,93,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
38,95,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
39,97,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
40,99,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
41,101,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
42,103,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
43,105,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
44,107,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
45,109,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
46,113,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
47,115,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
48,119,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
49,121,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
50,123,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
51,125,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
52,129,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
53,131,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
54,133,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
55,137,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
56,139,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
57,141,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
58,143,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
59,145,1,1,,443253,4189,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
60,192,1,1,,443253,4189,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
61,248,1,1,,443253,4189,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
62,357,2,1,,11112680,4189,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
63,410,1,5,,11112680,4189,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
64,411,2,1,,11112680,4189,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
65,444,1,1,,11112680,4189,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
66,445,3,1,,11112680,4189,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
67,446,1,1,,11112680,4189,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
68,447,1,1,,11112680,4189,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
69,448,1,2,,11112680,4189,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
70,450,1,2,,11112680,4189,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
71,451,1,2,,11112680,4189,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
72,526,1,1,,11112680,4189,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
73,530,1,1,,11112680,4189,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
74,584,1,3,,11112680,4189,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
75,585,1,4,,11112680,4189,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
76,587,1,5,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
77,588,1,4,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
78,589,1,3,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
79,590,1,3,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
80,591,1,4,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
81,592,1,6,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
82,593,1,4,,11112680,4189,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
83,594,1,4,,11112680,4189,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
84,595,1,3,,11112680,4189,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
85,596,1,2,,11112680,4189,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
86,597,1,3,,11112680,4189,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
87,603,1,2,,11112680,4189,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
88,605,1,2,,11112680,4189,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
89,607,1,3,,11112680,4189,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
90,662,1,1,,11112680,4189,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
91,875,1,2,,11112680,4189,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
92,880,2,1,,11112680,4189,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
93,880,2,1,,11112680,4189,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
94,881,2,2,,11112680,4189,Inactive,317373425.0,247.0,6.3096,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
95,883,1,3,,11112680,4189,Active,13699818.0,1559.0,0.3162,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
96,884,1,2,,11112680,4189,Active,13435386.0,1576.0,0.5012,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
97,885,1,2,,11112680,4189,Inactive,13435386.0,1576.0,0.5012,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
98,886,1,2,,11112680,4189,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
99,886,1,2,,11112680,4189,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
100,887,1,2,,11112680,4189,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
101,889,1,3,,11112680,4189,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
102,891,1,2,,11112680,4189,Active,40805836.0,1565.0,1.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
103,892,1,2,,11112680,4189,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
104,893,1,2,,11112680,4189,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
105,893,1,2,,11112680,4189,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
106,894,2,1,,11112680,4189,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
107,899,1,2,,11112680,4189,Active,4503219.0,1557.0,0.0251,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
108,900,1,3,,11112680,4189,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
109,901,1,2,,11112680,4189,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
110,902,1,2,,11112680,4189,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
111,912,1,2,,11112680,4189,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
112,914,1,3,,11112680,4189,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
113,915,1,3,,11112680,4189,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
114,923,1,2,,11112680,4189,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
115,924,1,2,,11112680,4189,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
116,925,1,2,,11112680,4189,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
117,926,1,2,,11112680,4189,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
118,927,1,3,,11112680,4189,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
119,938,1,2,,11112680,4189,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
120,995,1,2,,11112680,4189,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
121,1030,2,1,,11112680,4189,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
122,1195,1,2,,48416278,4189,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
123,1332,1,1,,49698872,4189,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
124,1379,1,2,,11112680,4189,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
125,1452,1,1,,11112680,4189,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
126,1454,1,1,,11112680,4189,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
127,1457,1,1,,11112680,4189,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
128,1458,1,1,,11112680,4189,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
129,1467,1,3,,11112680,4189,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
130,1469,1,1,,11112680,4189,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
131,1471,2,1,,11112680,4189,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
132,1476,2,1,,11112680,4189,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
133,1477,1,1,,11112680,4189,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
134,1478,2,1,,11112680,4189,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
135,1479,1,2,,11112680,4189,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
136,1487,1,1,,11112680,4189,Inconclusive,27436948.0,4000.0,0.0089,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
137,1490,2,1,,11112680,4189,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
138,1519,1,3,,11112680,4189,Inconclusive,,,19.9526,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
139,1688,1,1,,11112680,4189,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
140,1766,1,1,,11112680,4189,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
141,1766,1,1,,11112680,4189,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
142,1768,1,1,,11112680,4189,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
143,1768,1,1,,11112680,4189,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
144,1851,1,2,,11112680,4189,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
145,1851,1,2,1.0,11112680,4189,Active,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
146,1851,1,2,2.0,11112680,4189,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
147,1851,1,2,3.0,11112680,4189,Active,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
148,1851,1,2,4.0,11112680,4189,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
149,1851,1,2,5.0,11112680,4189,Active,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
150,1865,1,1,,11112680,4189,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
151,1948,1,1,,11112680,4189,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
152,2016,1,3,,85148356,4189,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
153,2023,1,3,,85148356,4189,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
154,2025,1,3,,85148356,4189,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
155,2029,1,3,,85148356,4189,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
156,2052,2,1,,85148356,4189,Active,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
157,2066,1,4,,85148356,4189,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
158,2101,1,1,,11112680,4189,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
159,2107,1,1,,11112680,4189,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
160,2112,1,1,,11112680,4189,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
161,2147,1,1,,11112680,4189,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
162,2240,1,1,,85788808,4189,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
163,2240,1,1,,85789203,4189,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
164,2241,1,1,,85788808,4189,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
165,2241,1,1,,85789203,4189,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
166,2275,1,1,,85788808,4189,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
167,2275,1,1,,85789203,4189,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
168,2280,2,3,,85148356,4189,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
169,2313,1,1,,85788808,4189,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
170,2313,1,1,,85789203,4189,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
171,2322,1,1,,85788808,4189,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
172,2322,1,1,,85789203,4189,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
173,2330,1,1,,85788808,4189,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
174,2330,1,1,,85789203,4189,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
175,2380,1,2,,85148356,4189,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
176,2435,1,2,,85148356,4189,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
177,2445,1,2,,85148356,4189,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
178,2451,1,2,,11112680,4189,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
179,2472,1,2,,11112680,4189,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
180,2517,2,1,,85148356,4189,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
181,2517,2,1,,144204152,4189,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
182,2520,1,4,,85148356,4189,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
183,2521,1,3,,85148356,4189,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
184,2524,1,2,,85148356,4189,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
185,2528,1,2,,11112680,4189,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
186,2540,1,2,,85148356,4189,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
187,2544,1,2,,85148356,4189,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
188,2546,1,1,,11112680,4189,Inconclusive,188536040.0,19885.0,11.2202,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
189,2549,1,1,,11112680,4189,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
190,2551,1,1,,11112680,4189,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
191,2557,1,3,,85148356,4189,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
192,2599,1,2,,85148356,4189,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
193,2606,1,2,,85148356,4189,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
194,2662,2,1,,11112680,4189,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
195,2690,1,2,,85148356,4189,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
196,2751,2,2,,85148356,4189,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
197,2796,1,4,,85148356,4189,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
198,2797,1,2,,85148356,4189,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
199,2805,2,2,,85148356,4189,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
200,2806,2,2,,85148356,4189,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
201,2810,1,1,,85148356,4189,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators for Cherry Picked Compounds from Primary Screen,Screening,,
202,2825,1,2,,85148356,4189,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
203,19468,3,3,,103171942,4189,Unspecified,,,,,Partition coefficient (logP),Other,12699389.0,
204,26810,3,3,,103171942,4189,Unspecified,,,,,Partition coefficient (logP),Other,4020834.0,
205,37557,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration towards Aspergillus fumigatus,Other,15125956.0,
206,37583,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger,Other,2810336.0,
207,37741,5,3,,103171942,4189,Unspecified,,,,,Compound was tested in vitro for antifungal activity against Aspergillus flavus.,Other,,
208,37743,6,3,,103171942,4189,Unspecified,,,,,Compound was tested in vitro for antifungal activity against Aspergillus fumigatus.,Other,,
209,39535,6,2,,103171942,4189,Active,,,1.9,IC50,Antimycotic activity against Aspergillus fumigatus was evaluated as compound minimum inhibitory concentration at which no macroscopic signs of fungal growth were detected.,Confirmatory,10411476.0,
210,39542,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus,Other,7310813.0,
211,39670,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus was determined in vitro,Other,3302258.0,
212,39671,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus,Other,14980639.0,
213,43431,10,2,,103171942,4189,Active,,,40.0,IC50,Compound was tested for the inhibition of beta-lactamase,Confirmatory,14521410.0,
214,43563,4,1,,103171942,4189,Unspecified,,,,,Fold decrease in IC50 vs beta-lactamase on pre-incubation,Other,14521410.0,
215,44954,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans was determined in vitro,Other,3302258.0,
216,44959,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans,Other,14980639.0,
217,44971,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 24 hr incubation,Other,14643323.0,
218,44972,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 48 hr incubation,Other,14643323.0,
219,44979,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans; Range is 8-16,Other,2810336.0,
220,44990,8,1,,103171942,4189,Active,,,,,Antimycotic activity against Candida albicans was evaluated as minimum inhibitory concentration of compound at which no macroscopic signs of fungal growth were detected,Other,10411476.0,
221,45134,6,2,,103171942,4189,Unspecified,,,,,Compound was evaluated for inhibitory activity against Candida albicans,Other,9873584.0,
222,45135,6,2,,103171942,4189,Unspecified,,,,,Compound was evaluated for inhibitory activity against Candida albicans; 1.6-2.0,Other,9873584.0,
223,45319,5,3,,103171942,4189,Unspecified,,,,,Compound was tested in vitro for antifungal activity against Candida albicans.,Other,,
224,45344,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 5.8,Other,12061875.0,
225,45345,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 7.2,Other,12061875.0,
226,45507,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against Candida albicans (40 clinical isolates), determined at pH-5.8",Other,7473549.0,
227,45508,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against Candida albicans (40 clinical isolates), determined at pH-7.2",Other,7473549.0,
228,47397,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans,Other,7310813.0,
229,47875,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis,Other,2810336.0,
230,47876,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis after 24 hr incubation,Other,14643323.0,
231,47877,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis after 48 hr incubation,Other,14643323.0,
232,47880,8,1,,103171942,4189,Active,,,,,Antimycotic activity against Candida parapsilosis was evaluated as compound concentration at which no macroscopic signs of fungal growth were detected,Other,10411476.0,
233,48047,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida parapsilosis at a pH of 5.7 using SDB medium,Other,1433223.0,
234,48066,8,1,,103171942,4189,Active,,,,,Antimycotic activity against Candida paratropicalis was evaluated. MIC was defined as compound concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
235,48077,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida pseudotropicalis; Range is 0.25-4,Other,2810336.0,
236,48242,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida rugosa,Other,2810336.0,
237,48245,3,4,,103171942,4189,Unspecified,,,,,Compound is evaluated for geometric mean of MIC values of Candida species,Other,1433223.0,
238,48249,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against Candida. species. (40 clinical isolates), determined at pH-5.8",Other,7473549.0,
239,48250,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against Candida. species. (40 clinical isolates), determined at pH-7.2",Other,7473549.0,
240,48251,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against Candida. species (40 clinical isolates), determined at pH-5.8",Other,7473549.0,
241,48253,6,2,,103171942,4189,Unspecified,,,,,50% inhibitory activity against the Candida. species (40 clinical isolates) was determined at pH-7.2,Other,7473549.0,
242,48256,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against Candida. species (40 clinical isolates), determined at pH-5.8",Other,7473549.0,
243,48258,6,2,,103171942,4189,Unspecified,,,,,90% inhibitory activity against Candida. species (40 clinical isolates) determined at pH-7.2,Other,7473549.0,
244,48259,3,3,,103171942,4189,Unspecified,,,,,Resistance against all Candida. species (40 clinical isolates) at 256 micro g/mL (pH=5.8). Activity is expressed as R%.,Other,7473549.0,
245,48260,3,3,,103171942,4189,Unspecified,,,,,"Percent resistance against all Candida. species (40 clinical isolates) at 256 micro g/mL (pH=7.2), activity is expressed as R%.",Other,7473549.0,
246,48264,6,2,,103171942,4189,Unspecified,,,,,Tested In vitro for antifungal activity against Candida species. at pH 7.2,Other,12061875.0,
247,48267,6,2,,103171942,4189,Unspecified,,,,,Tested in vitro for antifungal activity against Candida species. at pH 5.8,Other,12061875.0,
248,48269,6,2,,103171942,4189,Unspecified,,,,,Tested In vitro for antifungal activity against Candida species. at pH 7.2,Other,12061875.0,
249,48272,6,2,,103171942,4189,Unspecified,,,,,Tested in vitro for antifungal activity against Candida species. at pH 5.8,Other,12061875.0,
250,48274,6,2,,103171942,4189,Unspecified,,,,,Tested In vitro for antifungal activity against Candida species. at pH 7.2,Other,12061875.0,
251,48277,6,2,,103171942,4189,Unspecified,,,,,Tested in vitro for antifungal activity against Candida species. at pH 5.8,Other,12061875.0,
252,48422,5,1,,103171942,4189,Unspecified,,,,,Tested In vitro for antifungal activity against Candida species. at pH 7.2; (range is from 0.5 to 1),Other,12061875.0,
253,48444,5,1,,103171942,4189,Unspecified,,,,,Tested in vitro for antifungal activity against Candida species. at pH 5.8; value ranges from <0.25 to 0.25,Other,12061875.0,
254,48451,3,3,,103171942,4189,Unspecified,,,,,Tested In vitro for antifungal activity against Candida species. at pH 7.2; (percent of resistant species at 256 ug/mL),Other,12061875.0,
255,48453,3,3,,103171942,4189,Unspecified,,,,,Tested in vitro for antifungal activity against Candida species. at pH 5.8; (percent of resistant species at 256 ug/mL),Other,12061875.0,
256,48462,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida stellatoidea,Other,2810336.0,
257,48589,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida albicans at a pH of 5.7 using SDB medium,Other,1433223.0,
258,48591,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida albicans using eagles minimum essential medium (EMEM),Other,1433223.0,
259,48598,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida stellatoidea at a pH of 5.7 using SDB medium,Other,1433223.0,
260,48599,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida stellatoidea using eagles minimum essential medium (EMEM),Other,1433223.0,
261,48610,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida tropicalis,Other,7310813.0,
262,48631,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida tropicalis; Range is 8-16,Other,2810336.0,
263,48803,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida tropicalis at a pH of 5.7 using SDB medium,Other,1433223.0,
264,48804,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Candida tropicalis using eagles minimum essential medium (EMEM),Other,1433223.0,
265,49111,6,2,,103171942,4189,Unspecified,,,,,50% inhibitory activity against Candida albicans (40 clinical isolates) determined at pH-5.8,Other,7473549.0,
266,49112,7,2,,103171942,4189,Unspecified,,,,,50% inhibitory activity against Candida albicans (40 clinical isolates) determined at pH-7.2,Other,7473549.0,
267,49114,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 5.8,Other,12061875.0,
268,49115,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 7.2,Other,12061875.0,
269,49120,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against the Candida albicans (40 clinical isolates), determined at pH-5.8",Other,7473549.0,
270,49121,6,2,,103171942,4189,Unspecified,,,,,"Inhibitory activity against the Candida albicans (40 clinical isolates), determined at pH-7.2",Other,7473549.0,
271,49124,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 5.8,Other,12061875.0,
272,49125,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 7.2,Other,12061875.0,
273,49262,3,3,,103171942,4189,Unspecified,,,,,"Percent resistance against Candida albicans (40 clinical isolates) at 256 micro g/mL (pH=5.8), activity is expressed as R%.",Other,7473549.0,
274,49264,3,3,,103171942,4189,Unspecified,,,,,"Resistance against Candida. albicans (40 clinical isolates) at 256 ug/mL (pH=7.2), activity is expressed as R%.",Other,7473549.0,
275,49281,3,3,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 5.8; value ranges from <0.25 to 8,Other,12061875.0,
276,49288,5,1,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 7.2; minimum inhibitory concentration; value ranges from <0.25 to 16,Other,12061875.0,
277,49435,3,3,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 5.8; (percent of resistant species at 256 ug/mL),Other,12061875.0,
278,49436,3,3,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against 40 strains of Candida albicans at pH 7.2; (percent of resistant species (R) at 256 ug/mL),Other,12061875.0,
279,49465,3,3,,103171942,4189,Unspecified,,,,,Activity against Candida albicans ATCC 26278 strain in YNB medium after incorporation of 10 ug per disk expressed as zone size,Other,3309312.0,
280,49466,3,3,,103171942,4189,Unspecified,,,,,Activity against Candida albicans ATCC 26278 strain in YNB medium after incorporation of 20 ug per disk expressed as zone size,Other,3309312.0,
281,49626,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration towards Candida albicans,Other,15125956.0,
282,49635,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Candida albicans 3153,Other,6298430.0,
283,49641,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Candida albicans A,Other,6298430.0,
284,49645,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Candida albicans B,Other,6298430.0,
285,49650,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Candida albicans GB,Other,6298430.0,
286,49961,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata after 24 hr incubation,Other,14643323.0,
287,49962,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata after 48 hr incubation,Other,14643323.0,
288,50135,5,3,,103171942,4189,Unspecified,,,,,Compound was tested in vitro for antifungal activity against Candida kefyr.,Other,,
289,50322,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida neoformans after 24 hr incubation,Other,14643323.0,
290,50323,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida neoformans after 48 hr incubation,Other,14643323.0,
291,52776,9,2,,103171942,4189,Unspecified,,,125.0,IC50,Compound was tested for the inhibition of Chymotrypsinogen,Confirmatory,14521410.0,
292,53377,8,5,,103171942,4189,Active,117283.0,1586.0,0.243,Ki,In vitro inhibition of human Cytochrome P450 17A1 activity,Confirmatory,12773039.0,
293,54068,9,1,,103171942,4189,Active,,,0.4,EC50,In vitro inhibition of cytochrome P450 19A1 by rat ovarian microsomes incubated with [3H]androstenedione and NADPH-generating system.,Confirmatory,3612685.0,
294,54871,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans,Other,7310813.0,
295,54923,6,5,,103171942,4189,Active,,,0.18,IC50,Inhibition of human cytochrome P450 3A4,Confirmatory,12699389.0,
296,55014,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans,Other,14980639.0,
297,55019,8,1,,103171942,4189,Active,,,,,Antimycotic activity against Cryptococcus neoformans was evaluated. MIC was defined as compound concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
298,55024,6,3,,103171942,4189,Unspecified,,,,,Compound was tested in vitro for antifungal activity against Cryptococcus neoformans.,Other,,
299,55190,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration towards Cryptococcus neoformans,Other,15125956.0,
300,56602,3,4,,103171942,4189,Unspecified,,,,,Compound is evaluated for geometric mean of MIC values of dermatophytes,Other,1433223.0,
301,70079,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Epidermophyton floccosum at a pH of 5.7 using SDB medium,Other,1433223.0,
302,70206,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Epidermophyton floccosum,Other,6298430.0,
303,70215,3,9,,103171942,4189,Unspecified,123928.0,25315.0,,,Enhancement of epoxide hydrolase activity,Other,4020834.0,
304,70373,5,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Erysipelothrix insidiosa,Other,7310813.0,
305,71154,3,5,,103171942,4189,Unspecified,,,,,"Zone of inhibition from the edge of a circular filter disk impregnated with test substance, against Eurotium repens (antifungal activity)",Other,12086492.0,
306,77935,4,4,,103171942,4189,Unspecified,,,,,Lession score which is determined as number of animals minus days to become negative,Other,1433223.0,
307,78118,3,4,,103171942,4189,Unspecified,,,,,In vivo inhibition of topical Trichophyton infection in Guinea Pig after drug administration,Other,1433223.0,
308,78119,3,4,,103171942,4189,Unspecified,,,,,In vivo inhibition of topical Trichophyton infection in Guinea Pig during drug administration,Other,1433223.0,
309,85360,3,4,,103171942,4189,Unspecified,,,,,"Inhibition of Vaginal Candida (C-43 strain) infection in Hamsters, estimated as Percent Area under curve at 0.25 % concentration after 8 days of administration",Other,1433223.0,
310,85361,3,4,,103171942,4189,Unspecified,,,,,"Inhibition of Vaginal Candida (C-60 strain) infection in Hamsters, estimated as Percent Area under curve at 0.01 % concentration after 4 days of administration",Other,1433223.0,
311,85364,3,4,,103171942,4189,Unspecified,,,,,"Inhibition of Vaginal Candida (C-60 strain) infection in Hamsters, estimated as Percent Area under curve at 0.25 % concentration after 4 days of administration",Other,1433223.0,
312,85365,3,4,,103171942,4189,Unspecified,,,,,"Inhibition of Vaginal Candida (C-60 strain) infection in Hamsters, estimated as Percent Area under curve at 0.25 % concentration after 8 days of administration",Other,1433223.0,
313,106801,9,3,,103171942,4189,Active,,,25.0,IC50,Inhibition of malate dehydrogenase (MDH),Confirmatory,14521410.0,
314,125806,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis,Other,7310813.0,
315,125942,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Microsporum canis at a pH of 5.7 using SDB medium,Other,1433223.0,
316,125945,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Microsporum canis,Other,6298430.0,
317,125947,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis,Other,14980639.0,
318,125949,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration towards Microsporum canis,Other,15125956.0,
319,125959,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Microsporum gypseum at a pH of 5.7 using SDB medium,Other,1433223.0,
320,141780,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Mucor fragilis,Other,2810336.0,
321,141789,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Mucor species,Other,7310813.0,
322,150751,7,1,,103171942,4189,Unspecified,,,,,Inhibition of P-glycoprotein using ATPase in MDR1 membranes,Other,12699389.0,
323,150752,6,3,,103171942,4189,Active,,,3.5,IC50,"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
324,150753,6,3,,103171942,4189,Active,,,7.8,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
325,150754,6,3,,103171942,4189,Active,,,2.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
326,150755,6,3,,103171942,4189,Active,,,2.0,IC50,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Confirmatory,12699389.0,
327,150756,3,7,,103171942,4189,Unspecified,,,,,Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells,Other,12699389.0,
328,155489,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Phialophora verrucosa,Other,7310813.0,
329,200324,6,2,,103171942,4189,Unspecified,,,,,Compound was evaluated for inhibitory activity against Saccharomyces cerevisiae,Other,9873584.0,
330,200325,6,2,,103171942,4189,Unspecified,,,,,Compound was evaluated for inhibitory activity against Saccharomyces cerevisiae; 1.6-2.0,Other,9873584.0,
331,201551,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Saprolegnia species,Other,7310813.0,
332,202861,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae ATCC 7754,Other,14592492.0,
333,202868,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae ATCC 7754,Other,14592492.0,
334,204342,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Sporothrix schenck ii,Other,7310813.0,
335,204482,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against S. schenckii; no data,Other,14980639.0,
336,205796,7,1,,103171942,4189,Active,,,,,Fungicidal concentration on sterol 14-alpha-demethylase,Other,14521410.0,
337,206507,5,1,,103171942,4189,Unspecified,,,,,Antibacterial against Staphylococcus hemolyticus,Other,7310813.0,
338,208343,3,9,,103171942,4189,Unspecified,123928.0,25315.0,,,Enhanced styrene oxide hydrolase activity pH 8.7,Other,4020834.0,
339,208357,3,3,,103171942,4189,Unspecified,,,,,Maximum enhancement of styrene oxide hydrolase activity was reported at compound concentration of 5e-4 M,Other,4020834.0,
340,209120,5,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Streptococcus pyogenes,Other,7310813.0,
341,211162,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton asteroides was determined in vitro,Other,3302258.0,
342,211167,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes,Other,14980639.0,
343,211169,6,3,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration towards Trichophyton mentagrophytes,Other,15125956.0,
344,213465,3,5,,103171942,4189,Unspecified,,,,,"Zone of inhibition from the edge of a circular filter disk impregnated with test substance, against Ustilago violacea (antifungal activity)",Other,12086492.0,
345,214106,8,1,,103171942,4189,Active,,,,,Antimycotic activity against Trichophyton mentagrophytes was evaluated. MIC was defined as compound concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
346,214122,5,3,,103171942,4189,Unspecified,,,,,Compound was tested in vitro for antifungal activity against Trichophyton mentagrophytes.,Other,,
347,214276,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Trichophyton mentagrophytes at a pH of 5.7 using SDB medium,Other,1433223.0,
348,214288,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Trichophyton mentagrophytes,Other,6298430.0,
349,214429,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration against Trichophyton rubrum at a pH of 5.7 using SDB medium,Other,1433223.0,
350,214431,6,2,,103171942,4189,Unspecified,,,,,In vitro antifungal activity against Trichophyton rubrum,Other,6298430.0,
351,214806,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes,Other,7310813.0,
352,214807,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes,Other,2810336.0,
353,214822,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum,Other,7310813.0,
354,214823,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum,Other,2810336.0,
355,218567,4,1,,103171942,4189,Unspecified,,,,,Fold increase in IC50 vs beta-lactamase with 0.1 mg/mL saponin,Other,14521410.0,
356,218572,4,1,,103171942,4189,Unspecified,,,,,Fold increase in IC50 vs beta-lactamase with 10x increased enzyme,Other,14521410.0,
357,226461,3,4,,103171942,4189,Unspecified,,,,,"Geometric mean for the above three species of Candida, tested in EMEM medium",Other,1433223.0,
358,230887,3,3,,103171942,4189,Unspecified,,,,,"Ratio of animals cured to that of animals dead, Tested in vivo for antifungal activity against vaginal candidosis in rat; 0/6",Other,7310813.0,
359,230894,3,3,,103171942,4189,Unspecified,,,,,"Ratio of animals cured to that of animals infected, tested in vivo for antifungal activity against cutaneous candidosis in guinea pig; 4/13",Other,7310813.0,
360,244787,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity to inhibit Candida parapsilosis ATCC 22019,Other,15267229.0,
361,244792,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity to cause 99% reduction of surviving cells range is equal to 4-32,Other,15267229.0,
362,244861,6,2,,103171942,4189,Unspecified,,,,,In-vitro minimum inhibitory concentration against the growth of Candida albicans,Other,15913995.0,
363,244898,6,2,,103171942,4189,Unspecified,,,,,In-vitro minimum inhibitory concentration against the growth of Aspergillus fumigatus,Other,15913995.0,
364,244919,6,2,,103171942,4189,Unspecified,,,,,In-vitro minimum inhibitory concentration against the growth of Cryptococcus neoformans,Other,15913995.0,
365,244975,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration to inhibit Candida parapsilosis ATCC 22019,Other,15267229.0,
366,244978,6,2,,103171942,4189,Unspecified,,,,,In-vitro minimum inhibitory concentration against the growth of Trichophyton mentagrophytes,Other,15913995.0,
367,245175,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration to inhibit Candida albicans strain range is equal to 1-8,Other,15267229.0,
368,245682,6,2,,103171942,4189,Unspecified,,,,,In vitro minimal inhibitory concentration against Candida albicans with percentage of resistant strains %R = 33.33 (MIC > 64 ug/mL) at a range of 0.062-2 ug/mL,Other,16078834.0,
369,245919,6,2,,103171942,4189,Active,,,39.3,CC50,Cytotoxicity to reduce chronic myeloid leukemia K 562 cells,Confirmatory,15267229.0,
370,245920,6,2,,103171942,4189,Active,,,40.0,CC50,Cytotoxicity to reduce human histolytic lymphoma U937 cells,Confirmatory,15267229.0,
371,249257,7,1,,103171942,4189,Unspecified,,,,,Antifungal activity to cause 99% reduction of surviving cells in 50% isolates,Other,15267229.0,
372,249258,7,1,,103171942,4189,Unspecified,,,,,Antifungal activity to cause 99% reduction of surviving cells in 90% isolates,Other,15267229.0,
373,249259,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration to inhibit 50% of the isolates,Other,15267229.0,
374,249316,6,2,,103171942,4189,Unspecified,,,,,In vitro concentration causing 50% inhibition of Candida albicans with percentage of resistant strains %R = 33.33 (MIC > 64 ug/mL) at a range of 0.062-2 ug/mL,Other,16078834.0,
375,249325,6,2,,103171942,4189,Unspecified,,,,,Minimum inhibitory concentration to inhibit 90% of the isolates,Other,15267229.0,
376,249386,6,2,,103171942,4189,Unspecified,,,,,In vitro concentration causing 90% inhibition of Candida albicans with percentage of resistant strains %R = 33.33 (MIC > 64 ug/mL) at a range of 0.062-2 ug/mL,Other,16078834.0,
377,249459,3,3,,103171942,4189,Unspecified,,,,,Ratio of the in vitro minimal inhibitory to that of bifonazole against Candida albicans (MIC(compound)/MIC(bifonazole)),Other,16078834.0,
378,257544,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans,Other,16202590.0,
379,257545,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans,Other,16202590.0,
380,257546,7,2,,103171942,4189,Inconclusive,,,,,Antifungal activity against Sporothrix schenckii,Other,16202590.0,
381,257547,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes,Other,16202590.0,
382,257548,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus,Other,16202590.0,
383,257549,7,2,,103171942,4189,Inconclusive,,,,,Antifungal activity against Candida parapsilosis,Other,16202590.0,
384,283195,3,3,,103171942,4189,Unspecified,,,,,Susceptibility of Candida glabrata 21231 isolate at 10 ug by disk diffusion method,Other,17158937.0,
385,283196,3,3,,103171942,4189,Unspecified,,,,,Susceptibility of polyene-resistant Candida glabrata 21229 isolate at 10 ug by disk diffusion method,Other,17158937.0,
386,284511,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans,Other,17088068.0,
387,284512,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida pseudotropicalis,Other,17088068.0,
388,289115,3,3,,103171942,4189,Unspecified,,,,,Inhibition of CYP450-mediated tangeretin demethylation in Aspergillus niger ATCC 9142 assessed as relative activity at 0.5 mM,Other,17559266.0,
389,289312,7,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs,Other,17618124.0,
390,289313,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate after 24 hrs,Other,17618124.0,
391,289314,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs,Other,17618124.0,
392,289315,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Escherichia coli ATCC 23556 after 24 hrs,Other,17618124.0,
393,289316,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10145 after 48 hrs,Other,17618124.0,
394,289619,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus after 24 hrs by micro-broth dilution technique,Other,17084947.0,
395,289620,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Escherichia coli after 24 hrs by micro-broth dilution technique,Other,17084947.0,
396,289621,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Klebsiella pneumoniae after 24 hrs by micro-broth dilution technique,Other,17084947.0,
397,289622,7,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by micro-broth dilution technique,Other,17084947.0,
398,289623,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton tonsurans after 7 days,Other,17084947.0,
399,289624,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum gypseum after 7 days,Other,17084947.0,
400,294188,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10231 by macro-broth dilution assay,Other,17289382.0,
401,294189,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida krusei ATCC 6258 by macro-broth dilution assay,Other,17289382.0,
402,294191,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Escherichia coli ATCC 25922 at 100 ug/ml by diffusion method,Other,17289382.0,
403,294967,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 48 hrs by serial dilution method,Other,17337097.0,
404,294968,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by serial dilution method,Other,17337097.0,
405,294969,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata after 48 hrs by serial dilution method,Other,17337097.0,
406,298837,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans by dilution method,Other,17270436.0,
407,298838,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida pseudotropicalis by dilution method,Other,17270436.0,
408,309820,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida sp.,Other,17869507.0,
409,310053,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans 3038 after 24 hrs,Other,17888669.0,
410,310054,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans 3038 after 48 hrs,Other,17888669.0,
411,310055,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida glabrata 123 after 24 hrs,Other,17888669.0,
412,310056,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida glabrata 123 after 48 hrs,Other,17888669.0,
413,310100,8,1,,103171942,4189,Active,,,,,Antifungal activity against Aspergillus fumigatus by disc diffusion method,Other,17890082.0,
414,310101,8,1,,103171942,4189,Active,,,,,Antifungal activity against Penicillium marneffei by disc diffusion method,Other,17890082.0,
415,310102,8,1,,103171942,4189,Active,,,,,Antifungal activity against Candida albicans by disc diffusion method,Other,17890082.0,
416,310103,8,1,,103171942,4189,Active,,,,,Antifungal activity against Cryptococcus neoformans by disc diffusion method,Other,17890082.0,
417,310104,8,1,,103171942,4189,Active,,,,,Antifungal activity against Mucor sp. by disc diffusion method,Other,17890082.0,
418,311791,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus ATCC 9643 by microdilution technique,Other,17979247.0,
419,311792,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger ATCC 6275 by microdilution technique,Other,17979247.0,
420,311793,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus ochraceus ATCC 12066 by microdilution technique,Other,17979247.0,
421,311794,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Penicillium funiculosum ATCC 36839 by microdilution technique,Other,17979247.0,
422,311795,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Penicillium ochrochloron ATCC 9112 by microdilution technique,Other,17979247.0,
423,311796,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichoderma viride IAM 5061 by microdilution technique,Other,17979247.0,
424,311797,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium tricinctum CBS 514478 by microdilution technique,Other,17979247.0,
425,311798,8,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Alternaria alternata DSM 2006 by microdilution technique,Other,17979247.0,
426,311988,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium sphaerospermum after 72 hrs,Other,18031016.0,
427,311989,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium cladosporioides after 72 hrs,Other,18031016.0,
428,319919,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans PTCC 5027 after 24 to 48 hrs by agar dilution method,Other,18032039.0,
429,319920,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae PTCC 5177 after 24 to 48 hrs by agar dilution method,Other,18032039.0,
430,319921,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger PTCC 5012 after 72 hrs by agar dilution method,Other,18032039.0,
431,319922,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum gypseum PTCC 5070 after 168 hrs by agar dilution method,Other,18032039.0,
432,322753,9,5,,103171942,4189,Active,3915660.0,1595.0,0.2,IC50,Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay,Confirmatory,17194716.0,
433,327200,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus after 72 hrs,Other,18313934.0,
434,332622,3,4,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium cucumerinum assessed as inhibition of spore growth by TLC bioassay,Other,7760070.0,
435,333446,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium cladosporioides assessed as minimum concentration required to inhibit growth after 72 hrs by TLC,Other,15568762.0,
436,333447,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium sphaerospermum assessed as minimum concentration required to inhibit growth after 72 hrs by TLC,Other,15568762.0,
437,333793,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Botrytis cinerea,Other,15620255.0,
438,333794,6,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae,Other,15620255.0,
439,336237,3,4,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans at 10 ug/disk,Other,1710256.0,
440,336238,3,4,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes at 10 ug/disk,Other,1710256.0,
441,336891,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MSU-SM 920 after 2 to 4 days,Other,2509636.0,
442,336892,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis after 2 to 4 days,Other,2509636.0,
443,336893,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum after 2 to 4 days,Other,2509636.0,
444,337558,3,4,,103171942,4189,Active,,,,,Antifungal activity against Candida albicans after 16 to 19 hrs by disk diffusion assay in presence of 100 ppm ergosterol,Other,8450321.0,
445,338270,7,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans DSM 1665 after 18 hrs by twofold serial dilution method,Other,7714539.0,
446,338271,3,5,,103171942,4189,Inactive,,,,,Antimicrobial activity against Escherichia coli DSM 1103 after 18 hrs by twofold serial dilution method,Other,7714539.0,
447,338272,3,5,,103171942,4189,Inactive,,,,,Antimicrobial activity against Pseudomonas aeruginosa DSM 1117 after 18 hrs by twofold serial dilution method,Other,7714539.0,
448,348625,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 210923 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
449,348626,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Staphylococcus aureus NCTC 4163 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
450,348627,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 29213 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
451,348628,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 61038P at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
452,348629,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
453,348630,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Enterococcus hirae ATCC 101041 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
454,348631,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Escherichia coli ATCC 210922 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
455,348632,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Escherichia coli ATCC 101038 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
456,348633,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa NCTC 6749 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
457,348634,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 110442 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
458,348635,3,4,,103171942,4189,Inactive,,,,,Antibacterial activity against Bordetella bronchiseptica ATCC 4617 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
459,348636,3,4,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans ATCC 10231 at 10 ug/disk after 24 to 48 hrs by disc-diffusion method,Other,17950957.0,
460,352609,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 48 hrs by micro broth dilution method,Other,18708272.0,
461,352610,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans after 72 hrs by micro broth dilution method,Other,18708272.0,
462,352612,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes after 96 hrs by micro broth dilution method,Other,18708272.0,
463,352613,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus after 72 hrs by micro broth dilution method,Other,18708272.0,
464,355710,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MSU-SM 543 after 2 to 4 days,Other,2509636.0,
465,356322,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
466,356323,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis ATCC 22019 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
467,356324,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata ATCC 90030 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
468,356325,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida krusei ATCC 6258 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
469,356326,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans ATCC 90112 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
470,356327,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus IFM 41374 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
471,356328,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus IFM 41236 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
472,356329,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus nidulans IFM 5396 after 48 to 96 hrs by broth microdilution method,Other,12932139.0,
473,356330,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 after 48 hrs by disk diffusion assay,Other,12932139.0,
474,356332,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 at 10 ug/mL after 48 hrs by disk diffusion assay,Other,12932139.0,
475,356946,7,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes ATCC 28185 after 72 hrs by agar dilution method,Other,12502320.0,
476,356947,7,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichophyton rubrum ATCC 28188 after 72 hrs by agar dilution method,Other,12502320.0,
477,356948,7,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus niger ATCC 10335 after 48 hrs by agar dilution method,Other,12502320.0,
478,356949,7,2,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Candida albicans ATCC 10231 after 24 hrs by agar dilution method,Other,12502320.0,
479,359384,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans 44506 in Sabouraud dextrose broth after 18 to 24 hrs by twofold broth dilution method,Other,1479383.0,
480,359387,6,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans 44506 in RPMI-1640 medium after 18 to 24 hrs by twofold broth dilution method,Other,1479383.0,
481,361199,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 26790,Other,11429991.0,
482,372241,6,2,,103171942,4189,Active,,,,,Fungistatic activity against Candida albicans SSK21 after 24 to 48 hrs by broth microdilution assay,Other,17664325.0,
483,372243,6,2,,103171942,4189,Active,,,,,Fungistatic activity against Candida albicans CHK21 after 24 to 48 hrs by broth microdilution assay,Other,17664325.0,
484,373103,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans by bioautographic agar overlay method,Other,18672319.0,
485,373104,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae by bioautographic agar overlay method,Other,18672319.0,
486,375813,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans NCIM 3471 by agar plate assay,Other,19464891.0,
487,375814,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum NCIM 1332 by agar plate assay,Other,19464891.0,
488,375815,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus NCIM 539 by agar plate assay,Other,19464891.0,
489,375816,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger NCIM 1196 by agar plate assay,Other,19464891.0,
490,375817,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans NCIM 576 by agar plate assay,Other,19464891.0,
491,376227,4,3,,103171942,4189,Unspecified,,,,,Antibacterial activity against Bacillus megaterium at 50 ug/disk,Other,10924166.0,
492,376228,4,3,,103171942,4189,Unspecified,,,,,Antibacterial activity against Escherichia coli at 50 ug/disk,Other,10924166.0,
493,376231,4,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Microbotryum violaceae at 50 ug/disk,Other,10924166.0,
494,376232,4,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Eurotium repens at 50 ug/disk,Other,10924166.0,
495,376233,4,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum at 50 ug/disk,Other,10924166.0,
496,376234,4,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Mycotypha microspora at 50 ug/disk,Other,10924166.0,
497,376237,4,4,,103171942,4189,Unspecified,,,,,Antialgal activity against Chlorella fusca at 50 ug/disk,Other,10924166.0,
498,376662,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium cucumerinum after 3 days,Other,16724838.0,
499,377232,8,1,,103171942,4189,Active,,,,,Antifungal activity against Epidermophyton floccosum after 24 hrs,Other,11000021.0,
500,377233,8,1,,103171942,4189,Active,,,,,Antifungal activity against Trichophyton rubrum EL 5171 after 24 hrs,Other,11000021.0,
501,377234,8,1,,103171942,4189,Active,,,,,Antifungal activity against Trichophyton interdigitale EL 5171 after 24 hrs,Other,11000021.0,
502,377235,3,3,,103171942,4189,Inactive,,,,,Antifungal activity against Aspergillus niger ATCC 16404 at 1000 ug/ml after 24 hrs,Other,11000021.0,
503,377236,3,3,,103171942,4189,Inactive,,,,,Antifungal activity against Saccharomyces cerevisiae NCIMB 080178 at 1000 ug/ml after 24 hrs,Other,11000021.0,
504,377237,3,3,,103171942,4189,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10234 at 1000 ug/ml after 24 hrs,Other,11000021.0,
505,377238,3,3,,103171942,4189,Inactive,,,,,Antifungal activity against Penicillium notatum ATCC 11654 at 1000 ug/ml after 24 hrs,Other,11000021.0,
506,377239,3,3,,103171942,4189,Inactive,,,,,Antifungal activity against Scopulariopsis brevicaulis EL 936 at 1000 ug/ml after 24 hrs,Other,11000021.0,
507,377240,3,3,,103171942,4189,Inactive,,,,,Antifungal activity against Scytalidium dimidiatum at 1000 ug/ml after 24 hrs,Other,11000021.0,
508,378392,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Penicillium oxalicum at 0.8 ug,Other,16933872.0,
509,378407,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Penicillium oxalicum at 1.6 ug,Other,16933872.0,
510,378561,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Escherichia coli at 50 ug/filter disk,Other,15787461.0,
511,378562,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Bacillus megaterium at 50 ug/filter disk,Other,15787461.0,
512,378563,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Microbacterium violaceum at 50 ug/filter disk,Other,15787461.0,
513,378564,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Eurotium repens at 50 ug/filter disk,Other,15787461.0,
514,378565,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum at 50 ug/filter disk,Other,15787461.0,
515,378566,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Mycotypha microspora at 50 ug/filter disk,Other,15787461.0,
516,378567,3,4,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Chlorella fusca at 50 ug/filter disk,Other,15787461.0,
517,380196,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Eurotium repens at 50 ug/disk,Other,10395524.0,
518,380197,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum at 50 ug/disk,Other,10395524.0,
519,380198,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Ustilago violacea at 50 ug/disk,Other,10395524.0,
520,380199,3,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Mycotypha microspora at 50 ug/disk,Other,10395524.0,
521,380200,3,4,,103171942,4189,Unspecified,,,,,Antialgal activity against Chlorella fusca at 50 ug/disk,Other,10395524.0,
522,381888,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Alternaria alternata DMS2006 by serial dilution technique,Other,18280170.0,
523,381889,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus flavus ATCC 9643 by serial dilution technique,Other,18280170.0,
524,381890,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus niger ATCC 6275 by serial dilution technique,Other,18280170.0,
525,381891,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus ochraceus ATCC 12066 by serial dilution technique,Other,18280170.0,
526,381892,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Fusarium tricinctum by serial dilution technique,Other,18280170.0,
527,381893,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Penicillium funiculosum ATCC 36839 by serial dilution technique,Other,18280170.0,
528,381894,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Penicillium ochrochloron ATCC 9112 by serial dilution technique,Other,18280170.0,
529,381895,8,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichoderma viride IAM5061 by serial dilution technique,Other,18280170.0,
530,382505,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans by agar dilution method,Other,17499886.0,
531,382506,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida pseudotropicalis by agar dilution method,Other,17499886.0,
532,382685,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 at 480.6 uM by disc-diffusion method,Other,17531354.0,
533,382689,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 at 480.6 uM by disc-diffusion method,Other,17531354.0,
534,382693,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris at 480.6 uM by disc-diffusion method,Other,17531354.0,
535,382697,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae at 480.6 uM by disc-diffusion method,Other,17531354.0,
536,382701,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Enterobacter aerogenes at 480.6 uM by disc-diffusion method,Other,17531354.0,
537,382705,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 at 480.6 uM by disc-diffusion method,Other,17531354.0,
538,382709,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Staphylococcus epidermidis at 480.6 uM by disc-diffusion method,Other,17531354.0,
539,382713,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Streptococcus pyogenes at 480.6 uM by disc-diffusion method,Other,17531354.0,
540,382717,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Streptococcus agalactiae at 480.6 uM by disc-diffusion method,Other,17531354.0,
541,382721,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans ATCC 10231 at 480.6 uM by disc-diffusion method,Other,17531354.0,
542,382725,3,3,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus sp. at 480.6 uM by disc-diffusion method,Other,17531354.0,
543,382728,8,1,,103171942,4189,Active,,,,,Antimicrobial activity against Candida albicans ATCC 10231 after 24 hrs by microdilution assay,Other,17531354.0,
544,382874,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans 685 after 24 hrs,Other,18321714.0,
545,382875,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans 685 after 48 hrs,Other,18321714.0,
546,392755,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans 10145 after 2 to 5 days by tube dilution method,Other,19150600.0,
547,395111,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans isolate after 72 hrs by twofold serial dilution method,Other,19251421.0,
548,395112,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus isolate after 72 hrs by twofold serial dilution method,Other,19251421.0,
549,401713,3,3,,103171942,4189,Active,,,,,Antifungal activity against Cladosporium cladosporioides at 1 ug by TLC bioassay,Other,9677278.0,
550,402559,7,2,,103171942,4189,Unspecified,,,,,Antimycotic activity against Trichophyton mentagrophytes ATCC 28185 after 72 hrs,Other,15217270.0,
551,402560,7,2,,103171942,4189,Unspecified,,,,,Antimycotic activity against Trichophyton rubrum ATCC 28188 after 72 hrs,Other,15217270.0,
552,402561,7,2,,103171942,4189,Unspecified,,,,,Antimycotic activity against Aspergillus niger ATCC 10335 after 24 hrs,Other,15217270.0,
553,402562,7,2,,103171942,4189,Inconclusive,,,,,Antimycotic activity against Candida albicans ATCC 10231 after 48 hrs,Other,15217270.0,
554,403460,3,3,,103171942,4189,Active,,,,,Antifungal activity against Cladosporium cucumerinum at 10 ug,Other,9868150.0,
555,406950,9,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis ATCC 22019 at 35 degC after 48 hrs by broth microdilution test,Other,18529046.0,
556,406951,8,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10261 at 35 degC after 48 hrs by broth microdilution test,Other,18529046.0,
557,406952,6,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10261 at 35 degC after 48 to 96 hrs by broth microdilution test,Other,18529046.0,
558,406953,6,2,,103171942,4189,Unspecified,,,120.0,CC50,Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay,Confirmatory,18529046.0,
559,406954,6,2,,103171942,4189,Unspecified,,,80.0,CC50,Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay,Confirmatory,18529046.0,
560,406955,3,3,,103171942,4189,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human U937 cells to MIC90 for Candida albicans ATCC 10261",Other,18529046.0,
561,406956,3,4,,103171942,4189,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human K562 cells to MIC90 for Candida albicans ATCC 10261",Other,18529046.0,
562,406957,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against fluconazole-resistant Candida albicans isolated from oropharyngeal or vaginal disease patient after 48 hrs by broth microdilution test,Other,18529046.0,
563,406958,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against fluconazole-sensitive Candida albicans Fe40 at 35 degC after 48 hrs by broth microdilution test,Other,18529046.0,
564,406959,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against dermatophytes at 28 degC after 7 days by broth microdilution test,Other,18529046.0,
565,406960,5,1,,103171942,4189,Unspecified,,,,,Antifungal activity against dermatophytes at 35 degC after 48 to 96 hrs by broth microdilution test,Other,18529046.0,
566,416040,5,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness,Other,17620378.0,
567,416041,5,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness,Other,17620378.0,
568,419468,3,4,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans CAI4 at 6 ug/disk after 24 hrs by disk diffusion assay,Other,19409796.0,
569,428564,7,5,,103171942,4189,Active,,,0.85114,IC50,Inhibition of CYP3A4,Confirmatory,19128860.0,
570,434360,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 48 hrs by broth microdilution method,Other,19349095.0,
571,434361,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans after 72 hrs by broth microdilution method,Other,19349095.0,
572,434363,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against sTrichophyton mentagrophytes after 96 hrs by broth microdilution method,Other,19349095.0,
573,434364,7,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus after 72 hrs by broth microdilution method,Other,19349095.0,
574,434955,1,2,,85148356,4189,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
575,434959,1,1,,85788808,4189,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
576,434959,1,1,,85789203,4189,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
577,434962,1,2,,85148356,4189,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
578,434973,1,3,,85148356,4189,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
579,434989,1,1,,85148356,4189,Active,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
580,435003,1,3,,85148356,4189,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
581,435022,2,2,,85148356,4189,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
582,435030,1,2,,85148356,4189,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
583,435030,1,2,,85148356,4189,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
584,439881,6,6,,103171942,4189,Active,239938639.0,2916.0,6.5,IC50,Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay,Confirmatory,19819046.0,
585,444274,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against phytopathogenic Cladosporium cucumerinum by bioautographic TLC assay,Other,19811917.0,
586,449728,1,2,,85148356,4189,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
587,449762,1,2,,85148356,4189,Inconclusive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
588,449763,1,3,,85148356,4189,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
589,453203,3,4,,103171942,4189,Unspecified,,,,,"Lipophilicity, log D of the compound",Other,19963379.0,
590,453204,3,6,,103171942,4189,Unspecified,,,,,Permeability in human skin after 48 hrs by Franz cell permeability assay,Other,19963379.0,
591,454195,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans NCIM 347 by standard agar plate method,Other,20005098.0,
592,454196,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum NCIM 1332 by standard agar plate method,Other,20005098.0,
593,454197,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus NCIM 539 by standard agar plate method,Other,20005098.0,
594,454198,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger NCIM 1196 by standard agar plate method,Other,20005098.0,
595,454199,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans NCIM 576 by standard agar plate method,Other,20005098.0,
596,462891,5,2,,103171942,4189,Active,,,18.9,IC50,Inhibition of protein farnesyltransferase by continuous fluorescence assay,Confirmatory,20180535.0,
597,462892,3,3,,103171942,4189,Active,,,,,Blockade of protein farnesyltransferase by aggregate-based inhibition assay,Other,20180535.0,
598,462895,3,4,,103171942,4189,Active,,,,,Inhibition of protein farnesyltransferase-mediated farnesylation of GFP-tagged H-Ras protein overexpressed in MDCK cells assessed as inhibition of protein localization into golgi and plasma membrane at 10 uM after 48 hrs by Hoechst 34580 staining-based confocal microscopy,Other,20180535.0,
599,462897,3,4,,103171942,4189,Unspecified,,,,,Cytotoxicity against MDCK cells at >10 uM,Other,20180535.0,
600,463079,1,2,,85148356,4189,Active,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
601,463082,1,1,,85148356,4189,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
602,463104,1,2,,85148356,4189,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
603,463141,1,2,,85148356,4189,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
604,463190,1,2,,85148356,4189,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
605,463195,1,2,,85148356,4189,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
606,463210,1,2,,85148356,4189,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
607,463212,1,1,,85148356,4189,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
608,463254,1,1,,85148356,4189,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
609,463437,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichophyton longifusum after 7 days,Other,20005022.0,
610,463438,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans after 7 days,Other,20005022.0,
611,463440,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Microsporum canis after 7 days,Other,20005022.0,
612,463441,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Fusarium solani after 7 days,Other,20005022.0,
613,463442,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida glabrata after 7 days,Other,20005022.0,
614,479369,7,5,,103171942,4189,Active,117293.0,1588.0,0.6,IC50,Inhibition of human placental microsome CYP19,Confirmatory,20413308.0,
615,485270,1,1,,85148356,4189,Active,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
616,485272,1,1,,85148356,4189,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
617,485273,2,1,,85148356,4189,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
618,485275,1,3,,85148356,4189,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
619,485281,1,1,,11112680,4189,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
620,485290,1,1,,11112680,4189,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
621,485290,1,1,,85148356,4189,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
622,485341,1,1,,85148356,4189,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
623,485346,1,1,,85148356,4189,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
624,485346,1,1,,85148356,4189,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
625,485349,1,1,,85148356,4189,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
626,485350,1,2,,92125219,4189,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
627,485353,2,1,,85148356,4189,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
628,485360,1,1,,85148356,4189,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
629,485367,1,2,,85148356,4189,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
630,486886,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans ATCC 10231 by agar overlay technique,Other,20499922.0,
631,486963,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 48 hrs by micro broth dilution method,Other,20207052.0,
632,486964,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans after 72 hrs by micro broth dilution method,Other,20207052.0,
633,486966,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes after 96 hrs by micro broth dilution method,Other,20207052.0,
634,486967,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus after 72 hrs by micro broth dilution method,Other,20207052.0,
635,488837,1,1,,85148356,4189,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
636,488839,1,1,,85148356,4189,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
637,488839,1,1,,85148356,4189,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
638,488847,1,3,,85148356,4189,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
639,488862,1,1,,85148356,4189,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
640,488890,1,2,,85148356,4189,Inconclusive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
641,488895,1,2,,85148356,4189,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
642,488896,1,1,,85148356,4189,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
643,488899,1,1,,85148356,4189,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
644,488965,1,2,,85148356,4189,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
645,488966,1,1,,85148356,4189,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
646,489030,2,1,,85148356,4189,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
647,489031,2,1,,85148356,4189,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
648,489667,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton longifusum after 7 days,Other,20338672.0,
649,489668,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans after 7 days,Other,20338672.0,
650,489670,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis after 7 days,Other,20338672.0,
651,489671,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani after 7 days,Other,20338672.0,
652,489672,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata after 7 days,Other,20338672.0,
653,490025,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton longifusum at 200 ug/ml after 7 days,Other,20362358.0,
654,490026,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans at 200 ug/ml after 7 days,Other,20362358.0,
655,490028,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis at 200 ug/ml after 7 days,Other,20362358.0,
656,490029,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata at 200 ug/ml after 7 days,Other,20362358.0,
657,490031,6,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani at 200 ug/ml after 7 days,Other,20362358.0,
658,492947,1,1,,85148356,4189,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
659,492953,1,1,,85148356,4189,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
660,492956,1,1,,85148356,4189,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
661,492961,1,1,,11112680,4189,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
662,492967,1,2,,92125219,4189,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
663,492972,1,1,,85148356,4189,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
664,493005,1,1,,85148356,4189,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
665,493008,1,1,,85148356,4189,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
666,493008,1,1,,85148356,4189,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
667,493008,1,1,,85148356,4189,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
668,493008,1,1,,85148356,4189,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
669,493011,1,1,,85148356,4189,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
670,493012,1,1,,85148356,4189,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
671,493014,1,1,,85148356,4189,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
672,493033,1,2,,92125219,4189,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
673,493036,1,2,,85148356,4189,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
674,493087,1,1,,85148356,4189,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
675,493091,1,1,,85148356,4189,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
676,493098,1,1,,85148356,4189,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
677,493131,1,1,,85148356,4189,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
678,493140,1,1,,103913889,4189,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
679,493160,1,1,,85148356,4189,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
680,493187,1,2,,85148356,4189,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
681,493244,1,1,,85148356,4189,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
682,493244,1,1,,85148356,4189,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
683,493244,1,1,,85148356,4189,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
684,493244,1,1,,85148356,4189,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
685,504326,1,2,,85148356,4189,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
686,504326,1,2,,85148356,4189,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
687,504327,1,1,,11112680,4189,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
688,504327,1,1,,85148356,4189,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
689,504329,1,1,,85148356,4189,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
690,504332,1,1,,11112680,4189,Inconclusive,168985070.0,,7.9433,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
691,504339,1,1,,85148356,4189,Active,162330054.0,,39.8107,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
692,504357,1,1,,85148356,4189,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
693,504357,1,1,,85148356,4189,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
694,504411,1,1,,85148356,4189,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
695,504414,1,1,,85148356,4189,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
696,504414,1,1,,85148356,4189,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
697,504423,1,1,,85148356,4189,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
698,504441,1,1,,85148356,4189,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
699,504444,1,1,,85148356,4189,Inconclusive,224028257.0,4780.0,32.6427,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
700,504454,1,3,,85148356,4189,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
701,504462,1,1,,85148356,4189,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
702,504466,1,1,,85148356,4189,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
703,504467,1,1,,85148356,4189,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
704,504490,1,2,,85148356,4189,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
705,504523,1,1,,85148356,4189,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
706,504523,1,1,,85148356,4189,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
707,504558,1,1,,85148356,4189,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
708,504577,2,2,,85148356,4189,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
709,504582,2,1,,85148356,4189,Active,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
710,504621,1,1,,85148356,4189,Active,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
711,504634,1,1,,85148356,4189,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
712,504648,1,1,,85148356,4189,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
713,504690,1,3,,85148356,4189,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
714,504692,2,2,,85148356,4189,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
715,504700,1,1,,85148356,4189,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
716,504700,1,1,,85148356,4189,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
717,504706,1,1,,85148356,4189,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
718,504707,1,1,,85148356,4189,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
719,504707,1,1,,85148356,4189,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
720,504720,1,1,,85148356,4189,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
721,504734,1,1,,85148356,4189,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
722,504749,1,3,,11112680,4189,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
723,504749,1,3,1.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
724,504749,1,3,2.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
725,504749,1,3,3.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
726,504749,1,3,4.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
727,504749,1,3,5.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
728,504749,1,3,6.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
729,504749,1,3,7.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
730,504749,1,3,8.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
731,504749,1,3,9.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
732,504749,1,3,10.0,11112680,4189,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
733,504749,1,3,11.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
734,504749,1,3,12.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
735,504749,1,3,13.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
736,504749,1,3,14.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
737,504749,1,3,15.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
738,504749,1,3,16.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
739,504749,1,3,17.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
740,504749,1,3,18.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
741,504749,1,3,19.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
742,504749,1,3,20.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
743,504749,1,3,21.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
744,504749,1,3,22.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
745,504749,1,3,23.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
746,504749,1,3,24.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
747,504749,1,3,25.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
748,504749,1,3,26.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
749,504749,1,3,27.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
750,504749,1,3,28.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
751,504749,1,3,29.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
752,504749,1,3,30.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
753,504749,1,3,31.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
754,504749,1,3,32.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
755,504749,1,3,33.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
756,504749,1,3,34.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
757,504749,1,3,35.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
758,504749,1,3,36.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
759,504749,1,3,37.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
760,504749,1,3,38.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
761,504749,1,3,39.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
762,504749,1,3,40.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
763,504749,1,3,41.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
764,504749,1,3,42.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
765,504749,1,3,43.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
766,504749,1,3,44.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
767,504749,1,3,45.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
768,504749,1,3,46.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
769,504749,1,3,47.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
770,504749,1,3,48.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
771,504749,1,3,49.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
772,504749,1,3,50.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
773,504749,1,3,51.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
774,504749,1,3,52.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
775,504749,1,3,53.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
776,504749,1,3,54.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
777,504749,1,3,55.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
778,504749,1,3,56.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
779,504749,1,3,57.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
780,504749,1,3,58.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
781,504749,1,3,59.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
782,504749,1,3,60.0,11112680,4189,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
783,504749,1,3,61.0,11112680,4189,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
784,504766,2,1,,85148356,4189,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
785,504775,1,1,,85148356,4189,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
786,504803,1,1,,85148356,4189,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
787,504810,1,2,,85148356,4189,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
788,504812,1,2,,85148356,4189,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
789,504832,1,1,,11112680,4189,Inconclusive,,,5.1028,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
790,504834,1,1,,11112680,4189,Active,,,1.8106,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
791,504842,1,1,,85148356,4189,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
792,504845,1,1,,85148356,4189,Inconclusive,86301163.0,5999.0,89.1251,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
793,504847,1,1,,11112680,4189,Inconclusive,63054845.0,7421.0,35.4813,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
794,504847,1,1,,85148356,4189,Active,63054845.0,7421.0,79.4328,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
795,504865,1,1,,11112680,4189,Inconclusive,118600387.0,7398.0,28.1838,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
796,504884,1,2,,85148356,4189,Active,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
797,504891,1,1,,85148356,4189,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
798,504894,1,1,,85148356,4189,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
799,504937,1,2,,85148356,4189,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
800,515780,5,1,,103171942,4189,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
801,519606,6,1,,103171942,4189,Active,,,0.00203,IC50,Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs,Confirmatory,18212104.0,
802,519607,3,2,,103171942,4189,Unspecified,,,,,Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay,Other,18212104.0,
803,519608,1,4,,103171942,4189,Unspecified,,,,,"Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii",Other,18212104.0,
804,522126,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against deltacrz1 mutant containing Candida glabrata TG173 complemented with CRZ1 gene by colorimetric microdilution method,Other,20100876.0,
805,522127,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida glabrata TG172 containing deltacrz1 mutant by colorimetric microdilution method,Other,20100876.0,
806,522128,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against calcineurin deltacnb1 mutant containing Candida glabrata TG163 complemented with CNB1 gene by colorimetric microdilution method,Other,20100876.0,
807,522129,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against wild type Candida glabrata TG11 by colorimetric microdilution method,Other,20100876.0,
808,522130,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida glabrata TG162 containing calcineurin deltacnb1 mutant by colorimetric microdilution method,Other,20100876.0,
809,531537,1,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata clinical isolate obtained from cervicovaginal candidiasis patient assessed as susceptible isolates by broth microdilution method,Other,18591262.0,
810,531538,1,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata clinical isolate obtained from cervicovaginal candidiasis patient assessed as susceptible dose-dependent isolates by broth microdilution method,Other,18591262.0,
811,531540,1,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata clinical isolate overexpressing CDR1 gene obtained from cervicovaginal candidiasis patient assessed as resistant isolates by broth microdilution method,Other,18591262.0,
812,532528,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 2 ug/ml (Rvb = 0.157%),Other,18694951.0,
813,532550,5,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 by broth microdilution method,Other,18694951.0,
814,532552,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 1 ug/ml (Rvb = 0.157%),Other,18694951.0,
815,532553,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 0.5 ug/ml (Rvb = 0.157%),Other,18694951.0,
816,532559,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 2 ug/ml (Rvb = 0.144%),Other,18694951.0,
817,532560,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 1 ug/ml (Rvb = 0.144%),Other,18694951.0,
818,532561,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 0.5 ug/ml (Rvb = 0.144%),Other,18694951.0,
819,532565,5,2,,103171942,4189,Unspecified,,,,,Antifungal activity against wild-type Saccharomyces cerevisiae BY4741 by broth microdilution method,Other,18694951.0,
820,532571,2,3,,103171942,4189,Unspecified,,,,,"Antifungal activity against Candida glabrata isolate 21230 with silent mutations in ERG4, ERG5 genes and nonsense mutation in ERG6 gene by disk diffusion method",Other,18694952.0,
821,532572,2,3,,103171942,4189,Unspecified,,,,,Antifungal activity against wild-type Candida glabrata isolate 21231 by disk diffusion method,Other,18694952.0,
822,537733,2,3,,103171942,4189,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
823,537734,5,2,,103171942,4189,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
824,537735,2,3,,103171942,4189,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
825,537736,5,2,,103171942,4189,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
826,540253,1,1,,85148356,4189,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
827,540253,1,1,,85148356,4189,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
828,540253,1,1,,85148356,4189,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
829,540263,1,1,,85148356,4189,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
830,540263,1,1,,85148356,4189,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
831,540267,1,1,,85148356,4189,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
832,540268,1,1,,85148356,4189,Active,124809506.0,811999.0,0.195,AC50_uM,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
833,540270,1,1,,85148356,4189,Active,154146191.0,3320.0,0.195,AC50_uM,HsHsp90 Counterscreen Measured in Microorganism System Using Plate Reader - 2121-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
834,540295,1,1,,85148356,4189,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
835,540299,1,2,,92125219,4189,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
836,540303,1,1,,85148356,4189,Inconclusive,6679377.0,18792.0,12.5893,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
837,540303,1,1,,85148356,4189,Inconclusive,7242179.0,18793.0,12.5893,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
838,540303,1,1,,85148356,4189,Inconclusive,257471003.0,18815.0,12.5893,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
839,540308,1,1,,85148356,4189,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
840,540317,1,1,,85148356,4189,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
841,540336,1,1,,85148356,4189,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
842,540336,1,1,,85148356,4189,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
843,540364,1,2,,85148356,4189,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
844,550050,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as inhibition of visible growth after 48 hrs by agar dilution method,Other,21130647.0,
845,550051,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus assessed as inhibition of visible growth after 48 hrs by agar dilution method,Other,21130647.0,
846,550052,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger assessed as inhibition of visible growth after 48 hrs by agar dilution method,Other,21130647.0,
847,551056,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as macroscopically visible colonies after 48 and 72 hrs by standard agar dilution method,Other,21095127.0,
848,551057,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum assessed as macroscopically visible colonies after 48 and 72 hrs by standard agar dilution method,Other,21095127.0,
849,551058,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus assessed as macroscopically visible colonies after 48 and 72 hrs by standard agar dilution method,Other,21095127.0,
850,551059,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger assessed as macroscopically visible colonies after 48 and 72 hrs by standard agar dilution method,Other,21095127.0,
851,551060,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as appearance of macroscopically visible colonies after 48 and 72 hrs by standard agar dilution method,Other,21095127.0,
852,554705,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei B2399 after 48 hrs by liquid microdilution assay,Other,19015352.0,
853,554706,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei IFO0011 after 48 hrs by liquid microdilution assay,Other,19015352.0,
854,554707,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 89.021 after 48 hrs by liquid microdilution assay,Other,19015352.0,
855,554708,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 89.102 after 48 hrs by liquid microdilution assay,Other,19015352.0,
856,554709,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 89.221 after 48 hrs by liquid microdilution assay,Other,19015352.0,
857,554710,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 90.147 after 48 hrs by liquid microdilution assay,Other,19015352.0,
858,554711,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei B2399 after 48 hrs by CLSI method,Other,19015352.0,
859,554712,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei IFO0011 after 48 hrs by CLSI method,Other,19015352.0,
860,554713,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 89.021 after 48 hrs by CLSI method,Other,19015352.0,
861,554714,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 89.102 after 48 hrs by CLSI method,Other,19015352.0,
862,554715,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 89.221 after 48 hrs by CLSI method,Other,19015352.0,
863,554716,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida krusei NZCDC 90.147 after 48 hrs by CLSI method,Other,19015352.0,
864,554717,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p after 48 hrs by liquid microdilution assay,Other,19015352.0,
865,554718,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Saccharomyces cerevisiae ERG11 after 48 hrs by liquid microdilution assay,Other,19015352.0,
866,554719,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Candida albicans ERG11A after 48 hrs by liquid microdilution assay,Other,19015352.0,
867,554720,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae isolate AD overexpressing Candida krusei ERG11C after 48 hrs by liquid microdilution assay,Other,19015352.0,
868,554721,5,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Candida krusei ERG11g after 48 hrs by liquid microdilution assay,Other,19015352.0,
869,554722,5,2,,103171942,4189,Unspecified,,,,,"Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Saccharomyces cerevisiae ERG11 to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p",Other,19015352.0,
870,554723,5,2,,103171942,4189,Unspecified,,,,,"Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Candida albicans ERG11A to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p",Other,19015352.0,
871,554724,5,2,,103171942,4189,Unspecified,,,,,"Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Candida krusei ERG11C to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p",Other,19015352.0,
872,554725,5,2,,103171942,4189,Unspecified,,,,,"Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Candida krusei ERG11g to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p",Other,19015352.0,
873,554729,2,9,,103171942,4189,Inactive,121732831.0,,,,Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 0.026 nM,Other,19015352.0,
874,554933,2,3,,103171942,4189,Active,,,,,Increase in ERG11 mRNA expression in Candida krusei B2399 at 2 times MIC concentration after 1 hr by hot-phenol extraction based Northern blotting,Other,19015352.0,
875,560137,2,4,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata isolate 21231 at 10 ug after 48 hrs by disk diffusion method,Other,19380598.0,
876,560138,2,4,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata isolate 22852 at 10 ug after 48 hrs by disk diffusion method,Other,19380598.0,
877,560139,2,4,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata isolate 22853 at 10 ug after 48 hrs by disk diffusion method,Other,19380598.0,
878,572692,4,2,,103171942,4189,Active,,,1.16,Kd,Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 at pH7.5,Confirmatory,19075057.0,
879,572693,4,2,,103171942,4189,Active,,,0.94,Kd,Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 in presence of 0.5 M NaCl at pH7.5,Confirmatory,19075057.0,
880,572695,4,2,,103171942,4189,Active,,,2.48,Kd,Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 at pH7.5,Confirmatory,19075057.0,
881,572696,4,2,,103171942,4189,Active,,,5.57,Kd,Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 in presence of 0.5 M NaCl at pH7.5,Confirmatory,19075057.0,
882,572698,2,3,,103171942,4189,Unspecified,,,,,"Selectivity ratio, ratio of Kd for Mycobacterium smegmatis ATCC 700084 CYP164A2 to Kd for Mycobacterium smegmatis ATCC 700084 CYP51",Other,19075057.0,
883,572699,8,5,,103171942,4189,Active,613780401.0,888819.0,0.2,Kd,Binding affinity to Mycobacterium tuberculosis CYP51,Confirmatory,19075057.0,
884,572701,1,3,,103171942,4189,Unspecified,,,,,"Selectivity ratio, ratio of Kd for Mycobacterium smegmatis ATCC 700084 CYP164A2 to Kd for Mycobacterium tuberculosis CYP121",Other,19075057.0,
885,575456,4,2,,103171942,4189,Active,,,29.67,CC50,Cytotoxicity against human MRC5 cells,Confirmatory,20805398.0,
886,575457,4,2,,103171942,4189,Active,,,0.23,IC50,Antifungal activity against 5 x 10'6 CFU/ml Microsporum canis B68128 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
887,575458,4,2,,103171942,4189,Active,,,0.4,IC50,Antifungal activity against 5 x 10'6 CFU/ml Trichophyton mentagrophytes B70554 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
888,575459,4,2,,103171942,4189,Active,,,0.33,IC50,Antifungal activity against 5 x 10'6 CFU/ml Trichophyton rubrum B68183 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
889,575460,4,2,,103171942,4189,Active,,,0.14,IC50,Antifungal activity against 5 x 10'6 CFU/ml Trichophyton rubrum J941704 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
890,575461,4,2,,103171942,4189,Active,,,0.79,IC50,Antifungal activity against 5 x 10'6 CFU/ml Trichophyton quinckeanum B68683 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
891,575462,4,2,,103171942,4189,Active,,,0.3,IC50,Antifungal activity against 5 x 10'6 CFU/ml Candida albicans B59163 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
892,575463,4,2,,103171942,4189,Active,,,2.5,IC50,Antifungal activity against 5 x 10'6 CFU/ml Candida albicans B2630 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
893,575464,4,2,,103171942,4189,Active,,,0.12,IC50,Antifungal activity against 5 x 10'6 CFU/ml Candida glabrata B63155 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
894,575465,4,2,,103171942,4189,Active,,,0.03,IC50,Antifungal activity against 5 x 10'6 CFU/ml Candida kefyr B46120 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
895,575466,4,2,,103171942,4189,Active,,,1.4,IC50,Antifungal activity against 5 x 10'6 CFU/ml Candida krusei B68404 by resazurin based fluorimetry assay,Confirmatory,20805398.0,
896,575478,2,4,,103171942,4189,Active,,,,,Antifungal activity against 10'7 CFU/ml Candida albicans B2630 infected in vulvovaginitis rat model assessed as fungal burden at 10 mg/kg administered tropically twice daily measured after 3 days,Other,20805398.0,
897,575479,2,4,,103171942,4189,Active,,,,,Antifungal activity against 10'7 CFU/ml Candida albicans B2630 infected in vulvovaginitis rat model assessed as fungal burden at 5 mg/kg administered tropically twice daily measured after 3 days,Other,20805398.0,
898,588209,2,3,,103171942,4189,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
899,588210,2,4,,103171942,4189,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
900,588211,2,3,,103171942,4189,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
901,588212,2,3,,103171942,4189,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
902,588213,2,3,,103171942,4189,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
903,588334,1,1,,85148356,4189,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
904,588335,1,1,,85148356,4189,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
905,588352,1,2,,85148356,4189,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
906,588354,1,1,,85148356,4189,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
907,588358,1,2,,85148356,4189,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
908,588391,1,1,,85148356,4189,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
909,588405,1,1,,85148356,4189,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
910,588413,1,2,,85148356,4189,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
911,588436,1,1,,85148356,4189,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
912,588453,1,1,,85148356,4189,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
913,588456,1,1,,85148356,4189,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
914,588458,1,1,,85148356,4189,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
915,588473,1,1,,85148356,4189,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
916,588473,1,1,,85148356,4189,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
917,588475,1,2,,85148356,4189,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
918,588475,1,2,,85148356,4189,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
919,588478,1,2,,124800022,4189,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
920,588489,1,1,,85148356,4189,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
921,588492,1,1,,85148356,4189,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
922,588493,1,2,,85148356,4189,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
923,588497,1,2,,85148356,4189,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
924,588497,1,2,,85148356,4189,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
925,588497,1,2,,85148356,4189,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
926,588499,1,3,,85148356,4189,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
927,588499,1,3,,85148356,4189,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
928,588499,1,3,,85148356,4189,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
929,588501,1,2,,85148356,4189,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
930,588501,1,2,,85148356,4189,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
931,588501,1,2,,85148356,4189,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
932,588519,1,2,,92125219,4189,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
933,588525,1,2,,85148356,4189,Inconclusive,115347926.0,1175052.0,,AbsAC50_uM,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
934,588549,1,1,,85148356,4189,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
935,588579,1,1,,11112680,4189,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
936,588579,1,1,,85148356,4189,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
937,588590,1,1,,85148356,4189,Inconclusive,154350220.0,11201.0,7.0795,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
938,588591,1,1,,85148356,4189,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
939,588621,1,1,,85148356,4189,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
940,588664,1,2,,85148356,4189,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
941,588664,1,2,,85148356,4189,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
942,588674,1,2,,85148356,4189,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
943,588689,1,1,,85148356,4189,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
944,588692,2,1,,85148356,4189,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
945,588726,1,2,,85148356,4189,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
946,588727,1,1,,85148356,4189,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
947,588795,1,1,,85148356,4189,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
948,588814,1,3,,85148356,4189,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
949,588819,1,4,,85148356,4189,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
950,588834,2,1,,11112680,4189,Active,325651834.0,3757.0,4.4668,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
951,588850,1,1,,85148356,4189,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
952,588852,1,3,,85148356,4189,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
953,588855,1,1,,85148356,4189,Inconclusive,18418623.0,4088.0,35.4813,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
954,588856,1,1,,85148356,4189,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
955,589643,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans,Other,21324567.0,
956,589644,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans,Other,21324567.0,
957,589645,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum,Other,21324567.0,
958,589646,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus,Other,21324567.0,
959,589647,4,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger,Other,21324567.0,
960,593813,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae ATCC 9763 by broth dilution method,Other,21458275.0,
961,593814,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida tropicalis ATCC 1369 by broth dilution method,Other,21458275.0,
962,593900,4,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus niger ATCC 6275 by broth dilution method,Other,21458275.0,
963,595216,1,4,,103171942,4189,Unspecified,,,,,Antipromastigote activity against Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as luciferase activity of viable cells at 20 uM after 72 hrs by luminometry,Other,21385661.0,
964,595217,3,2,,103171942,4189,Active,,,6.0,IC50,Antiamastigote activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in mouse macrophage after 72 hrs by luciferase reporter gene assay,Confirmatory,21385661.0,
965,595218,3,2,,103171942,4189,Active,,,9.93,CC50,Cytotoxicity against mouse J774A1 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,21385661.0,
966,595219,1,4,,103171942,4189,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A.1 cells to IC50 for Leishmania donovani MHOM/IN/80/Dd8 amastigotes",Other,21385661.0,
967,597999,1,4,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans in yeast extract-peptone-glucose medium at 300 ug/ml after 48 hrs by disc diffusion assay,Other,21524574.0,
968,602123,1,1,,85148356,4189,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
969,602141,1,1,,85148356,4189,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
970,602162,1,1,,85148356,4189,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
971,602163,1,1,,85148356,4189,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
972,602179,1,2,,85148356,4189,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
973,602229,1,1,,85148356,4189,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
974,602233,1,1,,85148356,4189,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
975,602244,1,2,,85148356,4189,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
976,602247,1,2,,85148356,4189,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
977,602248,1,2,,85148356,4189,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
978,602250,1,2,,85148356,4189,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
979,602252,1,1,,85148356,4189,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
980,602252,1,1,,85148356,4189,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
981,602261,1,1,,85148356,4189,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
982,602274,1,2,,85148356,4189,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
983,602281,1,1,,85148356,4189,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
984,602281,1,1,,85148356,4189,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
985,602310,1,2,,85148356,4189,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
986,602313,1,1,,85148356,4189,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
987,602314,1,2,,92125219,4189,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
988,602329,1,1,,85148356,4189,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
989,602332,1,1,,11112680,4189,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
990,602332,1,1,,85148356,4189,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
991,602340,1,2,,85148356,4189,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
992,602342,2,1,,85148356,4189,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
993,602346,1,1,,85148356,4189,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
994,602363,1,1,,85148356,4189,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
995,602393,1,1,,85148356,4189,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
996,602396,1,2,,85148356,4189,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
997,602399,1,2,,85148356,4189,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
998,602405,1,1,,85148356,4189,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
999,602410,1,1,,85148356,4189,Active,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1000,602429,1,1,,85148356,4189,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1001,602438,1,1,,85148356,4189,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1002,602440,1,1,,85148356,4189,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1003,602449,1,2,,85148356,4189,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1004,602481,1,1,,85148356,4189,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1005,609822,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans,Other,21737269.0,
1006,609823,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger,Other,21737269.0,
1007,609824,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani,Other,21737269.0,
1008,609825,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus,Other,21737269.0,
1009,623870,1,1,,85148356,4189,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1010,623870,1,1,,85148356,4189,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1011,623877,1,1,,85148356,4189,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1012,623901,1,1,,85148356,4189,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1013,624030,1,2,,11112680,4189,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1014,624031,1,2,,11112680,4189,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1015,624032,1,2,,11112680,4189,Active,8393992.0,24660.0,8.7005,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1016,624037,1,3,,85148356,4189,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1017,624038,1,3,,85148356,4189,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1018,624040,1,3,,85148356,4189,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1019,624044,1,2,,11112680,4189,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1020,624101,1,2,,85788808,4189,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1021,624101,1,2,,85789203,4189,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1022,624125,1,4,,85148356,4189,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1023,624126,1,3,,85148356,4189,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1024,624127,1,2,,85148356,4189,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1025,624137,1,1,,85789203,4189,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1026,624151,1,1,,85788808,4189,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1027,624156,1,1,,85788808,4189,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1028,624156,1,1,,85789203,4189,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1029,624168,1,1,,85148356,4189,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1030,624169,1,1,,85148356,4189,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1031,624170,1,1,,11112680,4189,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1032,624170,1,1,,85148356,4189,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1033,624171,1,1,,85148356,4189,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1034,624172,1,1,,11112680,4189,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1035,624172,1,1,,85148356,4189,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1036,624173,1,3,,11112680,4189,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1037,624173,1,3,,85148356,4189,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1038,624178,1,1,,85148356,4189,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1039,624202,1,1,,85148356,4189,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1040,624204,1,2,,85148356,4189,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1041,624246,1,1,,85148356,4189,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1042,624256,1,2,,85148356,4189,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1043,624258,1,1,,85148356,4189,Inactive,458922.0,,,AbsAC40_uM,In vivo-based yeast HTS counterscreen to detect compounds rescuing yeast growth/survival of Saccharomyces cerevisiae SKN7-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1044,624260,1,1,,85789203,4189,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1045,624263,1,1,,85148356,4189,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1046,624263,1,1,,85148356,4189,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1047,624265,1,1,,85148356,4189,Inactive,,,,AbsAC35_uM,Mammalian cell toxicity counterscreen to identify toxic HSP40 inhibitor compounds in NIH3T3 cells Measured in Cell-Based System Using Plate Reader - 2120-03_Inhibitor_Dose_CherryPick_Activity_Set2,Confirmatory,,
1048,624267,1,2,,85148356,4189,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1049,624267,1,2,,85148356,4189,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1050,624268,1,3,,85148356,4189,Active,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1051,624288,1,1,,85148356,4189,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1052,624296,1,1,,11112680,4189,Inconclusive,7705682.0,51053.0,14.3194,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1053,624296,1,1,,85148356,4189,Inconclusive,7705682.0,51053.0,11.5821,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1054,624297,1,1,,11112680,4189,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1055,624297,1,1,,85148356,4189,Inconclusive,7705682.0,51053.0,10.3225,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1056,624304,1,2,,85148356,4189,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1057,624330,1,2,,85148356,4189,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1058,624349,1,2,,92125219,4189,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1059,624349,1,2,,92309037,4189,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1060,624349,1,2,,121362890,4189,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1061,624352,1,1,,85148356,4189,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1062,624354,1,1,,85148356,4189,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1063,624377,1,1,,85148356,4189,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1064,624412,1,2,,85148356,4189,Active,71746704.0,3662741.0,,,Luminescence-based biochemical high throughput confirmation assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1065,624413,1,1,,85148356,4189,Inactive,,,,,Counterscreen for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS): Luminescence-based cell-based high throughput assay to identify compounds that are cytotoxic to Jurkat human T lymphocyte cells,Screening,,
1066,624414,1,1,,85148356,4189,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1067,624415,1,2,,85148356,4189,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1068,624416,1,1,,85148356,4189,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1069,624417,1,1,,85148356,4189,Inconclusive,1724069.0,2740.0,12.5893,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1070,624418,1,1,,85148356,4189,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1071,624463,1,1,,85148356,4189,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1072,624464,1,1,,85148356,4189,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1073,624465,1,1,,85148356,4189,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1074,624466,1,3,,85148356,4189,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1075,624467,1,1,,85148356,4189,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1076,624483,1,1,,85148356,4189,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1077,625144,5,5,,103171942,4189,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1078,625145,4,7,,103171942,4189,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1079,625146,5,5,,103171942,4189,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1080,625147,4,7,,103171942,4189,Active,395398606.0,4159.0,18.485,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1081,625148,4,7,,103171942,4189,Active,60392672.0,4160.0,12.448,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1082,625149,4,7,,103171942,4189,Active,729996.0,4161.0,22.607,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1083,625150,5,5,,103171942,4189,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1084,625151,4,7,,103171942,4189,Active,113118.0,1128.0,3.971,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1085,625152,4,7,,103171942,4189,Active,113122.0,1129.0,4.336,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1086,625153,4,7,,103171942,4189,Active,113125.0,1131.0,3.154,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1087,625154,4,7,,103171942,4189,Active,23503039.0,1132.0,3.197,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1088,625155,4,7,,103171942,4189,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1089,625156,1,9,,103171942,4189,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1090,625157,6,2,,103171942,4189,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1091,625158,3,4,,103171942,4189,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1092,625159,5,5,,103171942,4189,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1093,625160,1,9,,103171942,4189,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1094,625161,4,7,,103171942,4189,Active,311033488.0,4985.0,3.387,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1095,625162,4,7,,103171942,4189,Active,116242691.0,4986.0,6.593999999999999,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1096,625163,4,7,,103171942,4189,Active,2851402.0,4988.0,6.059,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1097,625164,1,6,,103171942,4189,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1098,625165,3,4,,103171942,4189,Unspecified,,,73.911,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1099,625166,3,4,,103171942,4189,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1100,625167,5,5,,103171942,4189,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1101,625168,4,7,,103171942,4189,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1102,625169,1,6,,103171942,4189,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1103,625170,3,4,,103171942,4189,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1104,625171,4,7,,103171942,4189,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1105,625172,4,7,,103171942,4189,Active,75071465.0,,14.912,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1106,625173,5,5,,103171942,4189,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1107,625174,5,5,,103171942,4189,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1108,625175,5,5,,103171942,4189,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1109,625176,1,9,,103171942,4189,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1110,625177,5,5,,103171942,4189,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1111,625178,5,5,,103171942,4189,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1112,625179,1,9,,103171942,4189,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1113,625180,5,5,,103171942,4189,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1114,625181,5,5,,103171942,4189,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1115,625182,5,5,,103171942,4189,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1116,625183,5,5,,103171942,4189,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1117,625184,5,5,,103171942,4189,Active,2811086.0,1956.0,29.256,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1118,625185,5,5,,103171942,4189,Active,125370.0,2534.0,4.16,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1119,625186,5,5,,103171942,4189,Active,119533.0,2064.0,27.43,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1120,625187,5,5,,103171942,4189,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1121,625188,1,9,,103171942,4189,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1122,625189,1,7,,103171942,4189,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1123,625190,4,5,,103171942,4189,Active,,,11.472000000000001,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1124,625191,4,7,,103171942,4189,Active,112815.0,25075.0,20.6,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1125,625192,4,7,,103171942,4189,Active,543727.0,3356.0,3.907,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1126,625193,5,5,,103171942,4189,Active,113037.0,43.0,18.659000000000002,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1127,625194,4,7,,103171942,4189,Active,231473.0,134.0,12.519,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1128,625195,4,7,,103171942,4189,Active,543740.0,135.0,14.253,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1129,625196,5,6,,103171942,4189,Active,803374855.0,140.0,2.8110000000000004,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1130,625197,3,4,,103171942,4189,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1131,625198,4,7,,103171942,4189,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1132,625199,4,7,,103171942,4189,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1133,625200,4,7,,103171942,4189,Active,1168243.0,146.0,3.0460000000000003,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1134,625201,4,7,,103171942,4189,Active,1351829.0,150.0,3.966,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1135,625202,4,7,,103171942,4189,Active,613504690.0,151.0,3.5980000000000003,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1136,625203,4,7,,103171942,4189,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1137,625204,4,7,,103171942,4189,Active,48429211.0,153.0,12.635,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1138,625205,4,7,,103171942,4189,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1139,625206,4,7,,103171942,4189,Active,461604.0,155.0,5.482,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1140,625207,4,7,,103171942,4189,Active,128616.0,6530.0,2.9389999999999996,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1141,625208,5,5,,103171942,4189,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1142,625209,4,7,,103171942,4189,Active,1703214.0,186.0,23.986,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1143,625210,3,4,,103171942,4189,Active,,,19.279,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1144,625211,1,6,,103171942,4189,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1145,625212,3,4,,103171942,4189,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1146,625213,4,7,,103171942,4189,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1147,625214,1,9,,103171942,4189,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1148,625215,3,4,,103171942,4189,Active,,,18.034000000000002,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1149,625216,3,4,,103171942,4189,Active,,,6.266,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1150,625217,4,7,,103171942,4189,Active,1168220.0,3357.0,5.545,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1151,625218,4,7,,103171942,4189,Active,112816.0,3358.0,5.314,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1152,625219,3,4,,103171942,4189,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1153,625220,4,7,,103171942,4189,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1154,625221,4,7,,103171942,4189,Active,1703010.0,3362.0,10.887,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1155,625222,4,7,,103171942,4189,Active,400630.0,6532.0,0.778,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1156,625223,4,7,,103171942,4189,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1157,625224,3,4,,103171942,4189,Active,,,3.305,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1158,625225,3,4,,103171942,4189,Active,,,3.065,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1159,625226,4,7,,103171942,4189,Active,128359.0,6869.0,6.813,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1160,625227,4,7,,103171942,4189,Active,229462950.0,6865.0,4.8389999999999995,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1161,625228,4,7,,103171942,4189,Active,113832.0,24208.0,7.0889999999999995,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1162,625229,5,5,,103171942,4189,Active,254763392.0,6916.0,0.263,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1163,625230,1,6,,103171942,4189,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1164,625231,4,7,,103171942,4189,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1165,625232,1,9,,103171942,4189,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1166,625233,4,7,,103171942,4189,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1167,625234,3,4,,103171942,4189,Active,,,3.7880000000000003,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1168,625235,4,7,,103171942,4189,Active,115562.0,1268.0,21.05,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1169,625236,5,5,,103171942,4189,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1170,625237,4,7,,103171942,4189,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1171,625238,4,7,,103171942,4189,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1172,625239,4,7,,103171942,4189,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1173,625240,1,9,,103171942,4189,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1174,625241,4,7,,103171942,4189,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1175,625242,4,7,,103171942,4189,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1176,625243,5,5,,103171942,4189,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1177,625244,5,5,,103171942,4189,Active,3915797.0,5743.0,25.844,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1178,625245,5,5,,103171942,4189,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1179,625246,1,9,,103171942,4189,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1180,625247,5,5,,103171942,4189,Active,60416369.0,1557.0,0.016,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1181,625248,5,5,,103171942,4189,Active,6686268.0,1559.0,0.2,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1182,625249,5,5,,103171942,4189,Active,84028191.0,1565.0,1.0,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1183,625250,5,5,,103171942,4189,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1184,625251,5,5,,103171942,4189,Active,116241312.0,1576.0,0.1,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1185,625252,4,7,,103171942,4189,Active,118228.0,1812.0,6.247000000000001,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1186,625253,4,7,,103171942,4189,Active,118206.0,1813.0,12.504000000000001,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1187,625254,4,7,,103171942,4189,Active,1169206.0,1814.0,3.199,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1188,625255,4,7,,103171942,4189,Active,1345939.0,1815.0,15.27,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1189,625256,4,7,,103171942,4189,Active,266667.0,6531.0,1.7009999999999998,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1190,625257,4,7,,103171942,4189,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1191,625258,4,7,,103171942,4189,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1192,625259,4,7,,103171942,4189,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1193,625260,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1194,625261,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1195,625262,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1196,625263,4,7,,103171942,4189,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1197,625264,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1198,625265,1,6,,103171942,4189,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1199,625266,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1200,625267,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1201,625268,4,2,,103171942,4189,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1202,625268,4,2,,103171942,4189,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1203,625268,4,2,,103171942,4189,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1204,625268,4,2,,103171942,4189,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1205,625269,4,7,,103171942,4189,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1206,625270,4,7,,103171942,4189,Active,123120.0,3274.0,6.75,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1207,625271,5,5,,103171942,4189,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1208,625272,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1209,625273,4,6,,103171942,4189,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1210,625274,1,6,,103171942,4189,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1211,625275,3,4,,103171942,4189,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1212,625279,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1213,625280,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1214,625281,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1215,625282,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1216,625283,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1217,625284,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1218,625285,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1219,625286,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1220,625287,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1221,625288,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1222,625289,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1223,625290,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1224,625291,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1225,625292,1,3,,103171942,4189,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1226,625830,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans by broth microdilution method,Other,21930375.0,
1227,625831,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans by broth microdilution method,Other,21930375.0,
1228,625833,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes by broth microdilution method,Other,21930375.0,
1229,625834,3,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus by broth microdilution method,Other,21930375.0,
1230,628620,1,4,,103171942,4189,Inactive,,,,,Antimelanogenic activity in non-melanized Cryptococcus neoformans var. grubii assessed as inhibition of pigmentation at 0.5 ug/mL after 10 days by microtiter plate assay in presence of 1 mM catecholamine,Other,21715177.0,
1231,634087,4,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as morphogenetic transformation after 3 hrs by phase-contrast microscopy,Other,22100140.0,
1232,651550,1,1,,85148356,4189,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1233,651560,1,1,,85148356,4189,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1234,651572,1,2,,85148356,4189,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1235,651582,1,1,,85148356,4189,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1236,651602,1,1,,85148356,4189,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1237,651602,1,1,,85148356,4189,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1238,651602,1,1,,85148356,4189,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1239,651607,1,2,,85148356,4189,Active,71746704.0,3662741.0,,,Fluorescent Polarization-based biochemical high throughput orthogonal assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1240,651610,2,1,,85148356,4189,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1241,651631,4,1,,144204152,4189,Inconclusive,269849759.0,7157.0,11.3588,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1242,651632,4,1,,144204152,4189,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1243,651633,4,1,,144204152,4189,Inconclusive,,,14.2999,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1244,651634,4,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1245,651635,1,3,,85148356,4189,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1246,651636,1,1,,85148356,4189,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1247,651640,1,1,,85148356,4189,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1248,651644,1,1,,85148356,4189,Inconclusive,28872817.0,155807.0,63.0957,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1249,651647,1,1,,85148356,4189,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1250,651654,1,1,,85148356,4189,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1251,651658,1,1,,85148356,4189,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1252,651661,2,1,,85148356,4189,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1253,651687,1,1,,85148356,4189,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1254,651699,1,1,,85148356,4189,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1255,651699,1,1,,85148356,4189,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1256,651702,1,2,,85148356,4189,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1257,651704,2,1,,85148356,4189,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1258,651710,1,1,,85148356,4189,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1259,651711,2,1,,85148356,4189,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1260,651718,1,2,,85148356,4189,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1261,651723,1,1,,85148356,4189,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1262,651724,1,1,,85148356,4189,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1263,651725,1,1,,85148356,4189,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1264,651768,1,2,,85148356,4189,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1265,651800,1,1,,85148356,4189,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1266,651819,1,1,,85148356,4189,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1267,651820,1,1,,85148356,4189,Inconclusive,,,10.0,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1268,651821,2,4,,85148356,4189,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1269,651828,1,2,,92309037,4189,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1270,651957,1,1,,85148356,4189,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1271,651958,1,1,,85148356,4189,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1272,651965,1,1,,85148356,4189,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1273,651971,1,1,,85148356,4189,Inactive,71746704.0,3662741.0,11.743,IC50,Luminescence-based biochemical high throughput dose response assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Confirmatory,,
1274,651972,1,1,,85148356,4189,Inactive,,,33.01,IC50,Counterscreen for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS): Luminescence-based cell-based high throughput dose response assay to identify compounds that are cytotoxic to Jurkat human T lymphocyte cells,Confirmatory,,
1275,651989,1,1,,85148356,4189,Inactive,71746704.0,3662741.0,12.855,IC50,Counterscreen Fluorescent Polarization-based biochemical high throughput orthogonal dose response assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Confirmatory,,
1276,651999,1,1,,85148356,4189,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1277,652010,1,1,,85148356,4189,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1278,652017,1,1,,85148356,4189,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1279,652025,1,1,,85148356,4189,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1280,652039,1,1,,85148356,4189,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1281,652041,1,1,,85148356,4189,Active,,,1.95,AbsAC35_uM,Cell-based secondary assay to test the inhibitory activity of small molecule on Plasmodium flaciparum (HB3 strain) survival in red blood cells   Measured in Cell-Based System Using Plate Reader - 2120-06_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1282,652047,1,1,,85148356,4189,Active,,,1.52,AbsAC35_uM,Cell-based secondary assay to test the inhibitory activity of small molecule on Plasmodium flaciparum (3D7 strain) survival in red blood cells   Measured in Cell-Based System Using Plate Reader - 2120-05_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1283,652048,1,2,,85148356,4189,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1284,652048,1,2,,144204152,4189,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1285,652051,1,1,,85148356,4189,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1286,652051,1,1,,144204152,4189,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1287,652054,1,1,,85148356,4189,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1288,652067,1,4,,85148356,4189,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1289,652104,1,1,,85148356,4189,Inconclusive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1290,652105,1,1,,85148356,4189,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1291,652106,1,1,,85148356,4189,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1292,652115,1,1,,85148356,4189,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1293,652126,1,3,,85148356,4189,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1294,652154,1,1,,85148356,4189,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1295,652162,2,1,,85148356,4189,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1296,652163,1,1,,85148356,4189,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1297,652197,1,1,,85148356,4189,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1298,652257,1,1,,85148356,4189,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1299,658666,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans by agar well diffusion method,Other,22520258.0,
1300,658667,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger by agar well diffusion method,Other,22520258.0,
1301,658668,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani by agar well diffusion method,Other,22520258.0,
1302,658669,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus by agar well diffusion method,Other,22520258.0,
1303,662995,5,1,,103171942,4189,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at 250 ug/mL,Other,22607678.0,
1304,665066,1,3,,103171942,4189,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at > 256 ug/mL,Other,22560587.0,
1305,670550,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis MTCC 1744 after 24 hrs by well diffusion method,Other,22704888.0,
1306,670551,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida aaseri MTCC 1962 after 24 hrs by well diffusion method,Other,22704888.0,
1307,670552,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata MTCC 3019 after 24 hrs by well diffusion method,Other,22704888.0,
1308,670553,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 183 after 24 hrs by well diffusion method,Other,22704888.0,
1309,670554,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 7315 after 24 hrs by well diffusion method,Other,22704888.0,
1310,670555,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 3958 after 24 hrs by well diffusion method,Other,22704888.0,
1311,670556,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 854 after 24 hrs by well diffusion method,Other,22704888.0,
1312,681119,3,6,,103171942,4189,Unspecified,239938877.0,18671.0,7.8,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1313,681120,1,8,,103171942,4189,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells,Other,12699389.0,
1314,681122,3,6,,103171942,4189,Unspecified,238054374.0,5243.0,3.5,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1315,681128,3,6,,103171942,4189,Unspecified,126927.0,18669.0,2.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1316,681137,3,6,,103171942,4189,Unspecified,239938877.0,18671.0,22.2,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells,Confirmatory,12235267.0,
1317,681138,3,6,,103171942,4189,Unspecified,126927.0,18669.0,98.4,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells,Confirmatory,12235267.0,
1318,681142,3,6,,103171942,4189,Unspecified,238054374.0,5243.0,26.36,Ki,TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expressing LLC-PK1 cells,Confirmatory,11961113.0,
1319,681143,3,6,,103171942,4189,Unspecified,238054374.0,5243.0,55.5,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells,Confirmatory,11961113.0,
1320,686940,1,1,,85148356,4189,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1321,686964,1,1,,85148356,4189,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1322,686970,1,2,,85148356,4189,Active,49168486.0,3417.0,23.1093,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1323,686971,1,2,,85148356,4189,Inconclusive,,,18.3564,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1324,686977,2,1,,49698872,4189,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1325,686978,1,1,,85148356,4189,Active,79154014.0,55775.0,14.581,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1326,686978,1,1,,144204152,4189,Inconclusive,79154014.0,55775.0,12.7622,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1327,686979,1,1,,85148356,4189,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1328,686979,1,1,,144204152,4189,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1329,686992,2,1,,85148356,4189,Inconclusive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1330,686996,1,1,,85148356,4189,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1331,687014,1,1,,85148356,4189,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1332,687016,1,1,,85148356,4189,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1333,691207,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 2 to 3 days by modified agar well diffusion method,Other,22981334.0,
1334,691208,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 281 after 2 to 3 days by modified agar well diffusion method,Other,22981334.0,
1335,691209,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani MTCC 350 after 2 to 3 days by modified agar well diffusion method,Other,22981334.0,
1336,691210,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 after 2 to 3 days by modified agar well diffusion method,Other,22981334.0,
1337,696184,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 2 to 3 days by agar well diffusion method,Other,23026000.0,
1338,696185,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 281 after 2 to 3 days by agar well diffusion method,Other,23026000.0,
1339,696186,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani MTCC 350 after 2 to 3 days by agar well diffusion method,Other,23026000.0,
1340,696187,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 after 2 to 3 days by agar well diffusion method,Other,23026000.0,
1341,701459,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum,Other,22902032.0,
1342,701460,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton tonsurans,Other,22902032.0,
1343,701472,2,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida spp,Other,22902032.0,
1344,717725,1,4,,103171942,4189,Unspecified,,,,,Cytotoxicity against HEK293T cells assessed as decrease in cell viability at 25 uM after 24 hrs by trypan blue exclusion assay,Other,23122865.0,
1345,717840,1,7,,103171942,4189,Unspecified,221222505.0,56720.0,,,Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control,Other,23122865.0,
1346,717844,1,7,,103171942,4189,Unspecified,939108065.0,209176.0,,,Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control,Other,23122865.0,
1347,717845,4,5,,103171942,4189,Active,939108065.0,209176.0,6.7,IC50,Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis,Confirmatory,23122865.0,
1348,717846,4,5,,103171942,4189,Active,123949.0,15930.0,17.8,IC50,Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis,Confirmatory,23122865.0,
1349,720504,1,1,,85148356,4189,Inconclusive,21359873.0,5347.0,6.7016,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1350,720508,1,1,,85148356,4189,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1351,720509,1,1,,85148356,4189,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1352,720511,1,1,,85148356,4189,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1353,720516,2,1,,144204152,4189,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1354,720532,1,1,,144204152,4189,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1355,720533,1,1,,144204152,4189,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1356,720542,1,2,,85148356,4189,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1357,720543,1,1,,85148356,4189,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1358,720551,1,2,,85148356,4189,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1359,720552,2,1,,144204152,4189,Inconclusive,269849759.0,7157.0,13.4999,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1360,720553,1,2,,85148356,4189,Inconclusive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1361,720579,2,1,,85148356,4189,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1362,720580,1,1,,85148356,4189,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1363,720582,1,1,,85148356,4189,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1364,720596,1,1,,85148356,4189,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1365,720634,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1366,720635,2,1,,144204152,4189,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1367,720637,2,1,,144204152,4189,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1368,720641,1,2,,92309037,4189,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1369,720647,1,2,,85148356,4189,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1370,720648,1,1,,85148356,4189,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1371,720674,2,2,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1372,720675,2,2,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1373,720678,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1374,720679,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1375,720680,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1376,720681,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1377,720682,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1378,720683,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1379,720684,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1380,720685,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1381,720686,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1382,720687,2,2,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1383,720691,4,1,,144204152,4189,Inconclusive,311348376.0,2908.0,11.4554,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1384,720692,3,1,,144204152,4189,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1385,720693,3,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1386,720700,1,4,,85148356,4189,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1387,720702,1,1,,85148356,4189,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1388,720704,1,4,,85148356,4189,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1389,720706,1,2,,85148356,4189,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1390,720707,1,2,,85148356,4189,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1391,720708,1,2,,85148356,4189,Inconclusive,32171491.0,11069.0,39.8107,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1392,720709,1,2,,85148356,4189,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1393,720711,1,2,,85148356,4189,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1394,720717,1,3,,92125219,4189,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1395,720717,1,3,,92309037,4189,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1396,720719,2,1,,144204152,4189,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1397,720725,2,1,,144204152,4189,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1398,740185,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger NCIM 1196 by agar method,Other,23434418.0,
1399,740186,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans NCIM 3471 by agar method,Other,23434418.0,
1400,742597,2,2,,103171942,4189,Active,1169073.0,3641571.0,,,Cytochrome P450 51 inhibitor,Other,8834867.0,
1401,742597,2,2,,103171942,4189,Active,1169073.0,3641571.0,,,Cytochrome P450 51 inhibitor,Other,9564569.0,
1402,742597,2,2,,103171942,4189,Active,1169073.0,3641571.0,,,Cytochrome P450 51 inhibitor,Other,10515900.0,
1403,742597,2,2,,103171942,4189,Active,1169073.0,3641571.0,,,Cytochrome P450 51 inhibitor,Other,12366848.0,
1404,743012,3,1,,144204152,4189,Active,,,10.1235,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1405,743014,3,1,,144204152,4189,Active,,,11.3588,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1406,743015,3,1,,144204152,4189,Active,,,10.1235,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1407,743033,3,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1408,743035,2,1,,144204152,4189,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1409,743036,2,1,,144204152,4189,Inconclusive,124375976.0,367.0,10.2096,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1410,743040,3,1,,144204152,4189,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1411,743041,3,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1412,743042,3,1,,144204152,4189,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1413,743053,2,1,,144204152,4189,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1414,743054,2,1,,144204152,4189,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1415,743063,2,1,,144204152,4189,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1416,743064,3,1,,144204152,4189,Active,,,12.7448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1417,743065,3,1,,144204152,4189,Active,399498506.0,24831.0,11.3588,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1418,743066,3,1,,144204152,4189,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1419,743067,2,1,,144204152,4189,Inconclusive,399498506.0,24831.0,11.3588,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1420,743069,2,1,,144204152,4189,Inactive,348019627.0,2099.0,9.0993,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1421,743074,2,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1422,743075,2,1,,144204152,4189,Inactive,348019627.0,2099.0,11.4554,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1423,743077,2,1,,144204152,4189,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1424,743078,2,1,,144204152,4189,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1425,743079,3,1,,144204152,4189,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1426,743080,3,1,,144204152,4189,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1427,743081,3,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1428,743083,3,1,,144204152,4189,Active,119597822.0,1588.0,7.1669,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1429,743084,3,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1430,743085,3,1,,144204152,4189,Inconclusive,51095037.0,196.0,11.3588,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1431,743086,3,1,,144204152,4189,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1432,743091,2,1,,144204152,4189,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1433,743094,3,1,,144204152,4189,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1434,743122,2,1,,144204152,4189,Active,51095037.0,196.0,12.2649,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1435,743126,1,1,,85148356,4189,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1436,743139,2,1,,144204152,4189,Active,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1437,743140,2,1,,144204152,4189,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1438,743238,1,1,,85148356,4189,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1439,743244,1,1,,144204152,4189,Active,,,4.4788,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1440,743247,1,2,,85148356,4189,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1441,743255,1,1,,85148356,4189,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1442,743266,1,2,,85148356,4189,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1443,743269,1,1,,85148356,4189,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1444,743269,1,1,,85148356,4189,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1445,743279,1,2,,85148356,4189,Inconclusive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1446,743287,1,1,,85148356,4189,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1447,743322,2,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1448,743323,2,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1449,743324,2,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1450,743325,2,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1451,743326,2,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1452,743327,2,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1453,743344,1,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1454,743344,1,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1455,743345,1,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1456,743345,1,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1457,743346,1,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1458,743346,1,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1459,743347,1,1,,11112680,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1460,743347,1,1,,174007377,4189,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1461,743397,1,1,,85148356,4189,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1462,743398,1,1,,85148356,4189,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1463,746919,1,1,,103171942,4189,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for amastigotes of Leishmania donovani",Other,23582274.0,
1464,746920,1,1,,103171942,4189,Active,,,37.4,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,23582274.0,
1465,746921,1,1,,103171942,4189,Active,,,5.4,IC50,Antileishmanial activity against amastigotes of Leishmania donovani assessed as inhibition of parasite growth after 72 hrs by luciferase reporter assay,Confirmatory,23582274.0,
1466,746922,1,1,,103171942,4189,Unspecified,,,,,Antileishmanial activity against amastigotes of Leishmania donovani assessed as inhibition of parasite growth at 40 uM after 72 hrs by luciferase reporter assay,Other,23582274.0,
1467,747568,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 assessed as zone of inhibition at 100 ug/ml after 30 hrs by cup plate method,Other,23611733.0,
1468,747569,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 30 hrs by serial dilution method,Other,23611733.0,
1469,747570,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 assessed as zone of inhibition at 100 ug/ml after 30 hrs by cup plate method,Other,23611733.0,
1470,747571,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 after 30 hrs by serial dilution method,Other,23611733.0,
1471,747572,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MTCC 343 assessed as zone of inhibition at 100 ug/ml after 30 hrs by cup plate method,Other,23611733.0,
1472,747573,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MTCC 343 after 30 hrs by serial dilution method,Other,23611733.0,
1473,747574,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 assessed as zone of inhibition at 100 ug/ml after 30 hrs by cup plate method,Other,23611733.0,
1474,747575,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 after 30 hrs by serial dilution method,Other,23611733.0,
1475,752002,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger NCIM 1196 by agar dilution method,Other,23522562.0,
1476,752003,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus NCIM 539 by agar dilution method,Other,23522562.0,
1477,752004,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans NCIM 3471 by agar dilution method,Other,23522562.0,
1478,759604,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans NCIM 576 assessed as growth inhibition by agar dilution method,Other,23807083.0,
1479,759605,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger NCIM 1196 assessed as growth inhibition by agar dilution method,Other,23807083.0,
1480,759606,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus NCIM 539 assessed as growth inhibition by agar dilution method,Other,23807083.0,
1481,759607,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium oxysporum NCIM 1332 assessed as growth inhibition by agar dilution method,Other,23807083.0,
1482,759608,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans NCIM 3471 assessed as growth inhibition by agar dilution method,Other,23807083.0,
1483,766639,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Issatchenkia hanoiensis MTCC 4755 after 24 hrs by well diffusion method,Other,23911578.0,
1484,766640,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Issatchenkia orientalis MTCC 3020 after 24 hrs by well diffusion method,Other,23911578.0,
1485,766641,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida aaseri MTCC 1962 after 24 hrs by well diffusion method,Other,23911578.0,
1486,766642,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata MTCC 3019 after 24 hrs by well diffusion method,Other,23911578.0,
1487,766643,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida parapsilosis MTCC 1744 after 24 hrs by well diffusion method,Other,23911578.0,
1488,766644,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 7315 after 24 hrs by well diffusion method,Other,23911578.0,
1489,766645,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 4748 after 24 hrs by well diffusion method,Other,23911578.0,
1490,766646,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 3018 after 24 hrs by well diffusion method,Other,23911578.0,
1491,766647,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 3958 after 24 hrs by well diffusion method,Other,23911578.0,
1492,766648,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 3017 after 24 hrs by well diffusion method,Other,23911578.0,
1493,766649,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 1637 after 24 hrs by well diffusion method,Other,23911578.0,
1494,766650,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 854 after 24 hrs by well diffusion method,Other,23911578.0,
1495,766651,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 183 after 24 hrs by well diffusion method,Other,23911578.0,
1496,933081,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
1497,933082,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
1498,935097,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
1499,935098,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
1500,935099,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
1501,935100,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
1502,935101,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
1503,935102,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
1504,935103,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
1505,935104,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
1506,935105,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
1507,935106,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
1508,935107,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
1509,935108,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
1510,935109,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
1511,935110,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
1512,935111,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
1513,935112,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
1514,935113,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
1515,937581,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
1516,937582,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
1517,937583,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
1518,937584,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
1519,937585,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
1520,937586,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
1521,937587,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
1522,938218,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
1523,938219,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
1524,938220,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
1525,938221,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
1526,938222,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
1527,938223,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
1528,938224,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
1529,938225,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
1530,938226,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
1531,938227,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
1532,938228,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
1533,938229,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
1534,938230,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
1535,938231,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
1536,938232,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
1537,938233,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
1538,938234,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
1539,938235,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
1540,938236,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
1541,938237,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
1542,938238,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
1543,938239,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
1544,938240,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
1545,938241,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
1546,938242,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
1547,938243,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
1548,938244,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
1549,938245,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
1550,938246,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
1551,938247,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
1552,946241,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
1553,946242,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
1554,946243,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
1555,946244,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
1556,946245,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
1557,946246,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
1558,946247,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
1559,946248,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
1560,946249,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
1561,946250,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
1562,946251,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
1563,946252,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
1564,946253,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
1565,946254,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
1566,946255,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
1567,946256,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
1568,946257,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
1569,946258,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
1570,946259,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
1571,946260,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
1572,956972,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
1573,956973,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
1574,956974,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
1575,956975,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
1576,956976,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
1577,956977,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
1578,956978,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
1579,956979,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
1580,956980,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
1581,956981,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
1582,956982,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
1583,956983,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
1584,956984,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
1585,956985,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
1586,956986,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
1587,958870,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
1588,958871,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
1589,958872,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
1590,958873,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
1591,958874,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
1592,958875,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
1593,958876,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
1594,958877,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
1595,958878,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
1596,959449,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
1597,959450,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
1598,959451,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
1599,959452,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
1600,959453,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
1601,959454,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
1602,959455,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
1603,959456,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
1604,959457,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
1605,959458,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
1606,959459,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
1607,959460,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
1608,959461,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
1609,959462,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
1610,959463,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
1611,959464,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
1612,959465,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
1613,959466,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
1614,959467,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
1615,959468,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
1616,959469,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
1617,959470,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
1618,959471,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
1619,959472,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
1620,959473,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
1621,959474,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
1622,959475,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
1623,959476,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
1624,959477,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
1625,959478,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
1626,959479,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
1627,959480,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
1628,959481,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
1629,962380,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
1630,962381,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
1631,962382,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
1632,962383,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
1633,962384,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
1634,962385,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
1635,962386,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
1636,962387,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
1637,962388,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
1638,962754,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
1639,962755,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
1640,962756,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
1641,962757,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
1642,962758,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
1643,962759,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
1644,962760,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
1645,962761,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
1646,962762,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
1647,962763,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
1648,995705,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1649,995706,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1650,995707,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011016",Other,,
1651,995708,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011016",Other,,
1652,995709,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011016",Other,,
1653,995710,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011016",Other,,
1654,995711,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S011016",Other,,
1655,995712,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1656,995713,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S011016",Other,,
1657,995714,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S011016",Other,,
1658,995715,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
1659,995716,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011016",Other,,
1660,995717,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1661,995718,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1662,995719,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
1663,995720,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
1664,995721,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1665,995722,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
1666,995723,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1667,995724,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S011016",Other,,
1668,995725,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011016",Other,,
1669,995726,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011016",Other,,
1670,995727,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1671,995728,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
1672,995729,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1673,995730,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
1674,995731,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
1675,995732,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1676,995733,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011016",Other,,
1677,995734,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011016",Other,,
1678,995735,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011016",Other,,
1679,995736,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011016",Other,,
1680,995816,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1681,995817,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S011016",Other,,
1682,995818,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S011016",Other,,
1683,995819,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1684,995820,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011016",Other,,
1685,996401,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011016",Other,,
1686,996402,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011016",Other,,
1687,996403,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011016",Other,,
1688,996404,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
1689,996405,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
1690,996406,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
1691,996407,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
1692,996408,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1693,996409,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
1694,996410,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
1695,996411,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1696,996412,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
1697,996413,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1698,996414,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
1699,996415,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
1700,996416,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S011016",Other,,
1701,996417,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011016",Other,,
1702,996418,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011016,Other,,
1703,996419,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1704,996420,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1705,996421,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1706,996422,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1707,996423,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1708,996424,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1709,996425,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1710,996426,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1711,996427,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
1712,996428,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1713,996429,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1714,996430,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
1715,996431,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S011016",Other,,
1716,996432,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S011016",Other,,
1717,996433,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011016",Other,,
1718,996434,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011016",Other,,
1719,996435,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011016",Other,,
1720,998239,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
1721,998240,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1722,998241,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
1723,998242,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
1724,998243,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
1725,998244,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
1726,998245,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
1727,998246,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1728,998247,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1729,998248,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1730,998249,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
1731,998250,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
1732,998251,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1733,998252,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
1734,998253,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
1735,998254,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1736,998255,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1737,998256,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
1738,998257,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
1739,998258,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
1740,998259,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
1741,998840,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1742,998841,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
1743,998842,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
1744,998843,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1745,998844,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
1746,998845,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1747,998846,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1748,998847,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1749,998848,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
1750,998849,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1751,998850,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1752,998851,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011016,Other,,
1753,998852,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1754,998853,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
1755,998854,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
1756,998855,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
1757,998856,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1758,998857,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1759,998858,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1760,1000636,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1761,1000637,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
1762,1000638,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
1763,1000639,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
1764,1000640,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1765,1000641,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1766,1000642,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
1767,1000643,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
1768,1000661,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
1769,1000662,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1770,1000663,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
1771,1000664,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
1772,1000665,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
1773,1000666,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1774,1000667,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
1775,1000668,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1776,1000669,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1777,1000670,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1778,1000671,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
1779,1000672,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1780,1000673,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
1781,1000674,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
1782,1000675,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
1783,1000676,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1784,1000677,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1785,1000678,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1786,1000679,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
1787,1000680,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
1788,1000681,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
1789,1000682,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
1790,1000683,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1791,1000684,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
1792,1000685,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
1793,1000686,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
1794,1000687,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1795,1000688,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
1796,1000689,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
1797,1000690,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1798,1000691,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1799,1000692,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1800,1000693,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1801,1000694,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1802,1000695,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1803,1000696,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1804,1001276,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1805,1001277,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
1806,1001278,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1807,1001279,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1808,1002504,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
1809,1002505,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
1810,1002506,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1811,1002507,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
1812,1002508,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
1813,1002509,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1814,1002510,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1815,1002511,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
1816,1002512,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
1817,1002513,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1818,1002514,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1819,1002515,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1820,1003101,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1821,1003102,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1822,1003103,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1823,1003104,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1824,1003105,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
1825,1003106,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1826,1003107,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1827,1003108,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
1828,1003109,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1829,1003110,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
1830,1003111,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
1831,1003112,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
1832,1003113,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1833,1003114,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1834,1003115,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
1835,1003116,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
1836,1003117,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1837,1003118,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1838,1003119,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1839,1003120,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
1840,1003121,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
1841,1003122,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1842,1003123,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
1843,1003124,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
1844,1003125,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1845,1003126,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
1846,1003127,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
1847,1003128,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
1848,1003149,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011016",Other,,
1849,1003150,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S011016",Other,,
1850,1003151,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011016",Other,,
1851,1003152,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
1852,1003153,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
1853,1003154,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
1854,1003155,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1855,1003156,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
1856,1003157,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S011016",Other,,
1857,1003158,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1858,1003159,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011016",Other,,
1859,1003160,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011016",Other,,
1860,1003161,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1861,1003162,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S011016",Other,,
1862,1003163,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S011016",Other,,
1863,1003164,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
1864,1003165,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1865,1003166,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
1866,1003167,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1867,1003168,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1868,1003169,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1869,1003170,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1870,1003171,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
1871,1003172,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1872,1003173,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011016",Other,,
1873,1004995,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S011016",Other,,
1874,1004996,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S011016",Other,,
1875,1004997,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
1876,1004998,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
1877,1004999,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1878,1005000,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1879,1005001,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
1880,1005002,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S011016",Other,,
1881,1016474,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1882,1016475,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
1883,1016476,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
1884,1016477,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1885,1016478,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
1886,1016479,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
1887,1016480,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1888,1016481,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
1889,1016482,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
1890,1016483,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
1891,1016484,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
1892,1016485,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1893,1016486,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
1894,1017067,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
1895,1017068,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1896,1017069,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
1897,1017070,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1898,1017071,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1899,1017072,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1900,1017073,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
1901,1017074,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1902,1017075,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
1903,1017076,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
1904,1017077,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
1905,1017078,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1906,1017079,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
1907,1017080,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
1908,1017081,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
1909,1017082,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
1910,1017083,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1911,1017084,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
1912,1017085,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
1913,1017086,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1914,1017087,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1915,1017088,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
1916,1017089,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
1917,1017090,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1918,1017091,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1919,1017092,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1920,1017093,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1921,1018966,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1922,1018967,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1923,1018968,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
1924,1018969,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1925,1018970,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1926,1018971,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
1927,1018972,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1928,1018973,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
1929,1018974,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
1930,1019558,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
1931,1019559,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1932,1019560,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1933,1019561,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
1934,1019562,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
1935,1019563,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1936,1019564,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1937,1019565,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1938,1019566,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
1939,1019567,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
1940,1019568,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1941,1019569,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
1942,1019570,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
1943,1019571,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1944,1019572,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1945,1019573,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
1946,1019574,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1947,1019575,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
1948,1019576,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
1949,1019577,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
1950,1019578,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1951,1019579,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
1952,1019580,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
1953,1019581,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
1954,1019582,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1955,1019583,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
1956,1019584,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1957,1019585,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1958,1019586,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1959,1019587,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
1960,1019588,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1961,1021459,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
1962,1021460,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
1963,1021461,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
1964,1021462,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1965,1022044,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
1966,1022045,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
1967,1022046,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
1968,1022047,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
1969,1022048,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1970,1022049,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
1971,1022050,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
1972,1022051,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1973,1022052,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1974,1022053,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
1975,1022054,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
1976,1022055,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
1977,1022056,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1978,1022057,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1979,1022058,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
1980,1022059,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1981,1022060,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1982,1022061,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1983,1022062,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
1984,1022063,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1985,1022064,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
1986,1022065,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
1987,1022066,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1988,1022067,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
1989,1022068,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
1990,1022069,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
1991,1022070,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
1992,1022071,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1993,1022072,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
1994,1022073,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
1995,1022074,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
1996,1022075,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
1997,1022076,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
1998,1022077,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
1999,1022078,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
2000,1022079,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2001,1024511,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2002,1024512,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
2003,1024513,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
2004,1024514,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
2005,1024515,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2006,1024516,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2007,1024517,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
2008,1024518,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
2009,1024519,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
2010,1024520,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
2011,1024521,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2012,1024522,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
2013,1024523,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
2014,1024524,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2015,1024525,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
2016,1024526,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2017,1024528,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
2018,1024529,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
2019,1024530,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2020,1024531,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2021,1024532,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
2022,1024533,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
2023,1024534,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
2024,1024535,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
2025,1024536,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2026,1024537,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
2027,1024538,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
2028,1024539,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
2029,1024540,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2030,1024541,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
2031,1024542,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2032,1024543,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2033,1024544,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
2034,1024545,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
2035,1025109,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
2036,1025110,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
2037,1025111,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
2038,1025112,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2039,1025113,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2040,1025114,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
2041,1025115,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2042,1025116,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2043,1025117,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2044,1025118,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
2045,1025119,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2046,1025120,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
2047,1025121,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
2048,1025122,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2049,1025123,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
2050,1025124,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
2051,1025125,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
2052,1025126,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
2053,1025127,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2054,1025128,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
2055,1025129,1,3,,103171942,4189,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
2056,1025130,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
2057,1025131,1,3,,103171942,4189,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
2058,1053175,2,1,,178127377,4189,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2059,1053197,1,1,,85148356,4189,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2060,1058356,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans MTCC 3017 after 24 hrs by well diffusion method,Other,24206766.0,
2061,1058357,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Klebsiella planticola MTCC 530 after 24 hrs by well diffusion method,Other,24206766.0,
2062,1058358,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Pseudomonas aeruginosa MTCC 2453 after 24 hrs by well diffusion method,Other,24206766.0,
2063,1058359,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Escherichia coli MTCC 739 after 24 hrs by well diffusion method,Other,24206766.0,
2064,1058360,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Bacillus subtilis MTCC 121 after 24 hrs by well diffusion method,Other,24206766.0,
2065,1058361,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Staphylococcus aureus MLS-16 MTCC 2940 after 24 hrs by well diffusion method,Other,24206766.0,
2066,1058362,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Micrococcus luteus MTCC 2470 after 24 hrs by well diffusion method,Other,24206766.0,
2067,1058363,1,1,,103171942,4189,Inconclusive,,,,,Antimicrobial activity against Staphylococcus aureus MTCC 96 after 24 hrs by well diffusion method,Other,24206766.0,
2068,1063217,1,1,,103171942,4189,Unspecified,,,,,Antiproliferative activity against human DG75 cells at 10 uM after 72 hrs by Alamar blue assay,Other,24333581.0,
2069,1063218,1,1,,103171942,4189,Unspecified,,,,,Antiproliferative activity against human MUTU-I cells at 10 uM after 24 hrs by Alamar blue assay,Other,24333581.0,
2070,1063463,3,1,,103171942,4189,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as concentration required to decrease cell viability incubated for 24 hrs followed by compound washout measured after 18 hrs by resazurin dye-based assay,Other,24360560.0,
2071,1063464,3,1,,103171942,4189,Unspecified,,,,,Cytotoxicity against human FADU cells assessed as concentration required to decrease cell viability incubated for 24 hrs followed by compound washout measured after 18 hrs by resazurin dye-based assay,Other,24360560.0,
2072,1075994,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger NCIM 1196 by standard agar method,Other,24513045.0,
2073,1075995,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans NCIM 3471 by standard agar method,Other,24513045.0,
2074,1079931,1,1,,103171942,4189,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2075,1079932,1,1,,103171942,4189,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2076,1079933,1,1,,103171942,4189,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2077,1079934,1,1,,103171942,4189,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2078,1079935,1,1,,103171942,4189,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2079,1079936,1,1,,103171942,4189,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2080,1079937,1,1,,103171942,4189,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2081,1079938,1,1,,103171942,4189,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2082,1079939,1,1,,103171942,4189,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2083,1079940,1,1,,103171942,4189,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2084,1079941,1,1,,103171942,4189,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2085,1079942,1,1,,103171942,4189,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2086,1079943,1,1,,103171942,4189,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2087,1079944,1,1,,103171942,4189,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2088,1079945,1,1,,103171942,4189,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2089,1079946,1,1,,103171942,4189,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2090,1079947,1,1,,103171942,4189,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2091,1079948,1,1,,103171942,4189,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2092,1079949,1,1,,103171942,4189,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2093,1086109,1,2,,103171942,4189,Active,,,,,Antifungal activity against Candida albicans ATCC 10231 after 24 hr by broth microdilution method,Other,,
2094,1086617,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 after 28 to 30 hr by serial dilution method,Other,,
2095,1086618,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MTCC 343 at 6.25 to 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2096,1086619,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MTCC 343 after 28 to 30 hr by serial dilution method,Other,,
2097,1086620,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 at 6.25 to 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2098,1086622,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 after 28 to 30 hr by serial dilution method,Other,,
2099,1086641,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 at 6.25 to 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2100,1086642,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 28 to 30 hr by serial dilution method,Other,,
2101,1086643,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 at 6.25 to 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2102,1090229,3,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Zygosaccharomyces bailii assessed as growth inhibition measured after 48 hr by macrodilution assay,Other,15969495.0,
2103,1093847,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida glabrata assessed as fungus growth at 200 mg/ml by agar dilution method relative to control,Other,,
2104,1093848,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani assessed as fungus growth at 200 mg/ml by agar dilution method relative to control,Other,,
2105,1093849,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa assessed as bacterial growth at 200 mg/ml by agar dilution method relative to control,Other,,
2106,1093851,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as fungus growth at 200 mg/ml by agar dilution method relative to control,Other,,
2107,1093852,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton longifusum assessed as fungus growth at 200 mg/ml by agar dilution method relative to control,Other,,
2108,1093880,1,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Escherichia coli RSKK 313 at 3000 ug/ml after 18 to 24 hr by disk diffusion method,Other,,
2109,1093881,1,2,,103171942,4189,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 250 at 3000 ug/ml after 18 to 24 hr by disk diffusion method,Other,,
2110,1093882,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans RSKK 628 at 3000 ug/ml after 18 to 24 hr by disk diffusion method,Other,,
2111,1096456,1,2,,103171942,4189,Active,,,,,Antifungal activity against Aspergillus niger DSM 1988 after 24 to 48 hr by broth microdilution method,Other,,
2112,1096457,1,2,,103171942,4189,Active,,,,,Antifungal activity against Candida albicans DSM 1386 after 24 to 48 hr by broth microdilution method,Other,,
2113,1096872,1,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Fusarium solani at 200 ug/ml after 7 days by agar plate method,Other,,
2114,1096873,1,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Arthroderma otae at 200 ug/ml after 7 days by agar plate method,Other,,
2115,1096874,1,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichophyton longifusum at 200 ug/ml after 7 days by agar plate method,Other,,
2116,1096875,1,2,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans at 200 ug/ml after 7 days by agar plate method,Other,,
2117,1097178,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus by agar well diffusion method,Other,,
2118,1097179,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani by agar well diffusion method,Other,,
2119,1097180,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger by agar well diffusion method,Other,,
2120,1097181,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans by agar well diffusion method,Other,,
2121,1100599,1,2,,103171942,4189,Unspecified,,,65.0,IC50,Inhibition of recombinant Solanum lycopersicum (tomato) fatty acid 13-hydroperoxide lyase using (13S)-HPOT substrate by spectrophotometry,Confirmatory,66.0,
2122,1106498,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2123,1106499,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2124,1106500,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pseudomonas fluorescens ATCC 49838 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2125,1106501,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 13883 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2126,1106502,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 at 40 ug/disc after 18 to 24 hr by disk diffusion method,Other,,
2127,1106503,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 11778 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2128,1106504,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2129,1106505,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2130,1106506,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2131,1106507,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2132,1106513,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 at 40 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
2133,1106531,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 after 18 to 24 hr by broth microdilution method,Other,,
2134,1106532,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 to 24 hr by broth microdilution method,Other,,
2135,1106533,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hr by broth microdilution method,Other,,
2136,1106534,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 18 to 24 hr by broth microdilution method,Other,,
2137,1106535,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pseudomonas fluorescens ATCC 49838 after 18 to 24 hr by broth microdilution method,Other,,
2138,1106536,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Enterobacter aerogenes ATCC 13048 after 18 to 24 hr by broth microdilution method,Other,,
2139,1106537,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 to 24 hr by broth microdilution method,Other,,
2140,1106538,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 to 24 hr by broth microdilution method,Other,,
2141,1106539,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 to 24 hr by broth microdilution method,Other,,
2142,1106540,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 11778 after 18 to 24 hr by broth microdilution method,Other,,
2143,1106541,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 to 24 hr by broth microdilution method,Other,,
2144,1106566,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus,Other,,
2145,1106567,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani,Other,,
2146,1106568,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger,Other,,
2147,1106569,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans,Other,,
2148,1106602,1,2,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27855 after 24 hr by two-fold serial dilution method,Other,,
2149,1106604,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10231 after 7 days by two-fold serial dilution method,Other,,
2150,1107116,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 after 2 to 3 days by agar well diffusion method,Other,,
2151,1107117,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Fusarium solani MTCC 350 after 2 to 3 days by agar well diffusion method,Other,,
2152,1107118,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 281 after 2 to 3 days by agar well diffusion method,Other,,
2153,1107120,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 2 to 3 days by agar well diffusion method,Other,,
2154,1116405,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 28 to 30 hr by cup-plate method,Other,,
2155,1116406,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MTCC 343 after 28 to 30 hr by cup-plate method,Other,,
2156,1116407,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 after 28 to 30 hr by cup-plate method,Other,,
2157,1116408,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 after 28 to 30 hr by cup-plate method,Other,,
2158,1116416,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 at 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2159,1116417,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus flavus MTCC 277 at 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2160,1116418,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus MTCC 343 at 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2161,1116419,1,2,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 at 100 ug/ml after 28 to 30 hr by cup-plate method,Other,,
2162,1130374,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2163,1130375,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2164,1130376,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2165,1130377,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2166,1130378,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida tropicalis assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2167,1130379,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2168,1130380,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2169,1130381,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Sporothrix schenckii assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2170,1130382,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Saprolegnia Sp. assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2171,1130383,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Phialophora verrucosa assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2172,1130384,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Erysipelothrix insidiosa assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2173,1130385,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Staphylococcus haemolyticus assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2174,1130386,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Streptococcus pyogenes assessed as growth inhibition in sabouraud broth after 14 days,Other,490531.0,
2175,1130387,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis assessed as growth inhibition in sabouraud broth after 14 days in presence of 10% inactivated bovine serum,Other,490531.0,
2176,1130388,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes assessed as growth inhibition in sabouraud broth after 14 days in presence of 10% inactivated bovine serum,Other,490531.0,
2177,1130389,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida tropicalis assessed as growth inhibition in sabouraud broth after 14 days in presence of 10% inactivated bovine serum,Other,490531.0,
2178,1130390,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as growth inhibition in sabouraud broth after 14 days in presence of 10% inactivated bovine serum,Other,490531.0,
2179,1130391,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus assessed as growth inhibition in sabouraud broth after 14 days in presence of 10% inactivated bovine serum,Other,490531.0,
2180,1130392,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Sporothrix schenckii assessed as growth inhibition in sabouraud broth after 14 days in presence of 10% inactivated bovine serum,Other,490531.0,
2181,1133308,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum gypseum assessed as lowest concentration required for total inhibition broth dilution assay,Other,722748.0,
2182,1133309,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Epidermophyton floccosum assessed as lowest concentration required for total inhibition broth dilution assay,Other,722748.0,
2183,1133310,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes assessed as lowest concentration required for total inhibition broth dilution assay,Other,722748.0,
2184,1133311,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10231 assessed as lowest concentration required for total inhibition by broth dilution assay,Other,722748.0,
2185,1133312,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 14053 assessed as lowest concentration required for total inhibition by broth dilution assay,Other,722748.0,
2186,1133313,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as lowest concentration required for total inhibition by broth dilution assay,Other,722748.0,
2187,1133314,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 12600 assessed as lowest concentration required for total inhibition by broth microdilution assay,Other,722748.0,
2188,1133315,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis ATCC 14506 assessed as lowest concentration required for total inhibition by broth microdilution assay,Other,722748.0,
2189,1133316,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Corynebacterium acnes ATCC 11828 assessed as lowest concentration required for total inhibition by broth microdilution assay,Other,722748.0,
2190,1133317,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Erysipelothrix insidiosa ATCC 19414 assessed as lowest concentration required for total inhibition by broth microdilution assay,Other,722748.0,
2191,1133318,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Pasteurella multocida ATCC 19427 assessed as lowest concentration required for total inhibition by broth microdilution assay,Other,722748.0,
2192,1133319,1,1,,103171942,4189,Active,,,,,Antifungal activity against Candida albicans in mouse vaginal infection model compound applied intravaginally as 2% formulation in an aqueous propylene glycol cream for 4 days bid,Other,722748.0,
2193,1133320,1,1,,103171942,4189,Unspecified,,,,,"Lipophilic-hydrophilic balance, Rm of the compound assessed as change in compound Rm to miconazole Rm by reverse-phase TLC method",Other,722748.0,
2194,1146954,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 2% commercial cream formulation administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2195,1146955,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 2% commercial cream formulation administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2196,1146956,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 2% formulation administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2197,1146957,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 2% formulation administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2198,1146958,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 1% formulation administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2199,1146959,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 1% formulation administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2200,1146960,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 0.5% formulation administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2201,1146961,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 0.5% formulation administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2202,1146962,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 0.2% formulation administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2203,1146963,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 0.2% formulation administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2204,1146964,1,1,,103171942,4189,Inconclusive,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 0.1% formulation administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2205,1146965,1,1,,103171942,4189,Inconclusive,,,,,Antifungal activity against mixed infection of Candida albicans infected in mouse assessed as noninfected animals at 0.1% formulation administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2206,1146966,1,1,,103171942,4189,Unspecified,,,,,"Antifungal activity against Trichophyton mentagrophytes infected in guinea pig assessed as noninfected animals at 0.5% formulation in steryl alcohol, cetyl alcohol, Span 60, Tween 60, propylene glycol, mineral oil, and water administered qd for 5 days measured on day 4",Other,357722.0,
2207,1146967,1,1,,103171942,4189,Unspecified,,,,,"Antifungal activity against Trichophyton mentagrophytes infected in guinea pig assessed as noninfected animals at 0.5% formulation in steryl alcohol, cetyl alcohol, Span 60, Tween 60, propylene glycol, mineral oil, and water administered qd for 5 days measured on day 7",Other,357722.0,
2208,1146968,1,1,,103171942,4189,Unspecified,,,,,"Antifungal activity against Trichophyton mentagrophytes infected in guinea pig assessed as noninfected animals at 0.5% formulation in steryl alcohol, cetyl alcohol, Span 60, Tween 60, propylene glycol, mineral oil, and water administered qd for 5 days measured on day 14",Other,357722.0,
2209,1146993,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes assessed as growth inhibition by agar dilution method,Other,357722.0,
2210,1146994,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum assessed as growth inhibition by agar dilution method,Other,357722.0,
2211,1146995,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton tonsurans assessed as growth inhibition by agar dilution method,Other,357722.0,
2212,1146996,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton concentricum assessed as growth inhibition by agar dilution method,Other,357722.0,
2213,1146997,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum gypseum assessed as growth inhibition by agar dilution method,Other,357722.0,
2214,1146998,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis assessed as growth inhibition by agar dilution method,Other,357722.0,
2215,1146999,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Epidermophyton floccosum assessed as growth inhibition by agar dilution method,Other,357722.0,
2216,1147000,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition by broth dilution method,Other,357722.0,
2217,1147001,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 14053 assessed as growth inhibition by broth dilution method,Other,357722.0,
2218,1147002,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as growth inhibition by broth dilution method,Other,357722.0,
2219,1147003,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus No. 6538 P assessed as growth inhibition by broth microdilution method,Other,357722.0,
2220,1147004,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus No. 14154 assessed as growth inhibition by broth microdilution method,Other,357722.0,
2221,1147005,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis No. 8043-2 assessed as growth inhibition by broth microdilution method,Other,357722.0,
2222,1147006,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Streptococcus pyogenes No. 8668 assessed as growth inhibition by broth microdilution method,Other,357722.0,
2223,1147009,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 2% formulation in modified PEG 400 solution administered vaginally bid for 4 days measured on day 4 relative to placebo,Other,357722.0,
2224,1147010,1,1,,103171942,4189,Inactive,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 2% formulation in modified PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2225,1147011,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 4% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2226,1147012,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 4% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2227,1147013,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 2% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2228,1147014,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 2% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2229,1147015,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 1% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2230,1147016,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 1% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2231,1147017,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 0.5% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2232,1147018,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 0.5% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2233,1147019,1,1,,103171942,4189,Inconclusive,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 0.25% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo,Other,357722.0,
2234,1147020,1,1,,103171942,4189,Inconclusive,,,,,Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 0.25% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo,Other,357722.0,
2235,1150035,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2236,1150036,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2237,1150037,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2238,1150038,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2239,1150039,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida tropicalis assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2240,1150040,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2241,1150041,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Mucor species assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2242,1150042,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2243,1150043,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Sporothrix schenckii assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2244,1150044,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Saprolegnia species assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2245,1150045,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Phialophora verrucosa assessed as lowest dose level for total inhibition of fungal growth,Other,915916.0,
2246,1150046,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Erysipelothrix insidiosa assessed as lowest dose level for total inhibition of bacterial growth,Other,915916.0,
2247,1150047,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Staphylococcus haemolyticus assessed as lowest dose level for total inhibition of bacterial growth,Other,915916.0,
2248,1150048,1,1,,103171942,4189,Unspecified,,,,,Antibacterial activity against Streptococcus pyogenes assessed as lowest dose level for total inhibition of bacterial growth,Other,915916.0,
2249,1150050,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Microsporum canis assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2250,1150051,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton mentagrophytes assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2251,1150052,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Trichophyton rubrum assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2252,1150053,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2253,1150054,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida tropicalis assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2254,1150055,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Candida albicans assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2255,1150056,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Mucor species assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2256,1150057,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2257,1150058,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Sporothrix schenckii assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2258,1150059,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Saprolegnia species assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2259,1150060,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Phialophora verrucosa assessed as lowest dose required to total inhibition of fungal growth,Other,915917.0,
2260,1150061,1,1,,103171942,4189,Unspecified,,,,,Antibaterial activity against Erysipelothrix insidiosa assessed as lowest dose required to total inhibition of bacterial growth,Other,915917.0,
2261,1150062,1,1,,103171942,4189,Unspecified,,,,,Antibaterial activity against Staphylococcus haemolyticus assessed as lowest dose required to total inhibition of bacterial growth,Other,915917.0,
2262,1150063,1,1,,103171942,4189,Unspecified,,,,,Antibaterial activity against Streptococcus pyogenes assessed as lowest dose required to total inhibition of bacterial growth,Other,915917.0,
2263,1153405,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Micrococcus luteus MTCC 2470 after 24 hrs by well diffusion method,Other,24835633.0,
2264,1153406,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Staphylococcus aureus MTCC 96 after 24 hrs by well diffusion method,Other,24835633.0,
2265,1153407,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Staphylococcus aureus MLS-16 MTCC 2940 after 24 hrs by well diffusion method,Other,24835633.0,
2266,1153408,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Bacillus subtilis MTCC 121 after 24 hrs by well diffusion method,Other,24835633.0,
2267,1153409,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Escherichia coli MTCC 739 after 24 hrs by well diffusion method,Other,24835633.0,
2268,1153410,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Pseudomonas aeruginosa MTCC 2453 after 24 hrs by well diffusion method,Other,24835633.0,
2269,1153411,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Klebsiella planticola MTCC 530 after 24 hrs by well diffusion method,Other,24835633.0,
2270,1153412,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans MTCC 3017 after 24 hrs by well diffusion method,Other,24835633.0,
2271,1155374,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium cladosporioides after 48 hrs,Other,24905499.0,
2272,1155375,1,1,,103171942,4189,Unspecified,,,,,Antifungal activity against Cladosporium sphaerospermum after 48 hrs,Other,24905499.0,
2273,1156862,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans after 48 hrs by microbroth dilution method,Other,24992075.0,
2274,1156863,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus fumigatus after 72 hrs by microbroth dilution method,Other,24992075.0,
2275,1156864,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Cryptococcus neoformans after 72 hrs by microbroth dilution method,Other,24992075.0,
2276,1156865,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Sporothrix schenckii after 72 hrs by microbroth dilution method,Other,24992075.0,
2277,1156866,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes after 96 hrs by microbroth dilution method,Other,24992075.0,
2278,1159524,1,1,,85148356,4189,Inconclusive,,,28.1838,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2279,1159580,2,1,,268734626,4189,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2280,1159583,2,1,,178127377,4189,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
2281,1159606,1,1,,85148356,4189,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2282,1159607,2,1,,312309760,4189,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2283,1159620,1,1,,103171942,4189,Active,,,,,Summary of drug indications.,Other,,
2284,1162420,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Saccharomyces cerevisiae ATCC 9763 up to 100 ug/ml after 48 hrs by two-fold broth dilution method,Other,25180924.0,
2285,1162421,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Candida tropicalis ATCC 1369 up to 100 ug/ml after 48 hrs by two-fold broth dilution method,Other,25180924.0,
2286,1162422,1,1,,103171942,4189,Inactive,,,,,Antimicrobial activity against Aspergillus niger ATCC 6275 up to 100 ug/ml after 48 hrs by two-fold broth dilution method,Other,25180924.0,
2287,1162423,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae ATCC 9763 after 48 hrs by two-fold broth dilution method,Other,25180924.0,
2288,1162424,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida tropicalis ATCC 1369 after 48 hrs by two-fold broth dilution method,Other,25180924.0,
2289,1162425,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus niger ATCC 6275 after 48 hrs by two-fold broth dilution method,Other,25180924.0,
2290,1164257,1,2,,103171942,4189,Active,60416369.0,1557.0,17.9,IC50,Inhibition of human recombinant CYP2C19 incubated for 5 mins by fluorescence assay,Confirmatory,25221656.0,
2291,1180299,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Candida albicans NCIM-3471 after 20 hrs by two fold serial macrodilution technique,Other,24951333.0,
2292,1180300,1,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against Candida albicans NCIM-3471 after 48 to 72 hrs by two fold serial macrodilution technique,Other,24951333.0,
2293,1180301,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus flavus NCIM-539 after 20 hrs by two fold serial macrodilution technique,Other,24951333.0,
2294,1180302,1,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against Aspergillus flavus NCIM-539 after 48 to 72 hrs by two fold serial macrodilution technique,Other,24951333.0,
2295,1180303,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Aspergillus niger NCIM-1196 after 20 hrs by two fold serial macrodilution technique,Other,24951333.0,
2296,1180304,1,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against Aspergillus niger NCIM-1196 after 48 to 72 hrs by two fold serial macrodilution technique,Other,24951333.0,
2297,1180305,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Cryptococcus neoformans NCIM-3378 after 20 hrs by two fold serial macrodilution technique,Other,24951333.0,
2298,1180306,1,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against Cryptococcus neoformans NCIM-3378 after 48 to 72 hrs by two fold serial macrodilution technique,Other,24951333.0,
2299,1181454,1,2,,103171942,4189,Active,60416369.0,1557.0,18.0,IC50,Inhibition of recombinant human CYP2C19 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Confirmatory,24974340.0,
2300,1181469,1,2,,103171942,4189,Unspecified,60416369.0,1557.0,,,Inhibition of recombinant human CYP2C19 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Other,24974340.0,
2301,1184068,1,2,,103171942,4189,Active,123948.0,3620.0,6.7,IC50,Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC,Confirmatory,25036789.0,
2302,1184069,1,2,,103171942,4189,Active,123948.0,3620.0,3.8,IC50,Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins in presence of 0.01% Triton-X by HPLC,Confirmatory,25036789.0,
2303,1184070,1,2,,103171942,4189,Inactive,123949.0,15930.0,,IC50,Inhibition of mouse IDO1 expressed in mouse P815B cells using L-tryptophan substrate incubated for 18 hrs by HPLC based cellular assay,Confirmatory,25036789.0,
2304,1184071,1,2,,103171942,4189,Inactive,221222505.0,56720.0,,IC50,Inhibition of mouse TDO expressed in mouse P815B cells using L-tryptophan substrate incubated for 24 hrs by HPLC based cellular assay,Confirmatory,25036789.0,
2305,1184072,1,1,,103171942,4189,Active,,,10.0,LD50,Cytotoxicity against mouse P815B cells after 24 hrs by MTS/PMS assay,Confirmatory,25036789.0,
2306,1184074,1,1,,103171942,4189,Active,,,,,Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO,Other,25036789.0,
2307,1184075,1,2,,103171942,4189,Unspecified,123948.0,3620.0,,,Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC,Other,25036789.0,
2308,1189129,1,1,,103171942,4189,Active,,,0.04,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
2309,1189130,1,1,,103171942,4189,Active,,,15.44,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
2310,1189131,1,1,,103171942,4189,Unspecified,,,62.74,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
2311,1189132,1,1,,103171942,4189,Active,,,23.89,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in primary peritoneal mouse macrophages",Confirmatory,,
2312,1189133,1,1,,103171942,4189,Active,,,36.6,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
2313,1189134,1,1,,103171942,4189,Active,,,4.39,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
2314,1189135,1,1,,103171942,4189,Active,,,10.79,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
2315,1189136,1,1,,103171942,4189,Active,,,0.49,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
2316,1196913,1,1,,103171942,4189,Inconclusive,,,,,Fungicidal activity against Trichophyton mentagrophytes B70554,Other,25585716.0,
2317,1196914,1,1,,103171942,4189,Inconclusive,,,,,Fungicidal activity against Trichophyton rubrum B68183,Other,25585716.0,
2318,1196915,1,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against Microsporum canis B68128,Other,25585716.0,
2319,1196916,1,1,,103171942,4189,Unspecified,,,,,Fungicidal activity against Sporothrix schenckii B62482,Other,25585716.0,
2320,1209987,1,2,,103171942,4189,Active,21264413.0,1573.0,0.64,IC50,"Inhibition of CYP2J2 in human liver microsomes using 7 probe cocktail containing phenacetin, paclitaxel, diclofenac, S-mephenytoin, dextromethorphan, astemizole and midazolam after 8 mins by LC-MS/MS analysis",Confirmatory,22328583.0,
2321,1209990,1,2,,103171942,4189,Active,21264413.0,1573.0,0.58,IC50,Inhibition of CYP2J2-mediated astemizole O-demethylation in human liver microsomes after 8 mins by LC-MS/MS analysis,Confirmatory,22328583.0,
2322,1210013,1,2,,103171942,4189,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control,Other,22328583.0,
2323,1210014,1,2,,103171942,4189,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2324,1224824,1,1,,174007377,4189,Inactive,,,7.4266,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2325,1224825,1,1,,174007377,4189,Inactive,,,93.4955,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2326,1224857,2,1,,174007377,4189,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2327,1224859,2,1,,174007377,4189,Inactive,,,4.6859,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2328,1224863,1,1,,176484411,4189,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2329,1224863,1,1,,176484745,4189,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2330,1224863,1,1,,176485039,4189,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2331,1224863,1,1,,316920396,4189,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2332,1224865,1,2,,85148356,4189,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
2333,1224905,2,1,,92309037,4189,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2334,1224905,2,1,,92309037,4189,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2335,1237442,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus MLS16 MTCC 2940 incubated for 24 hrs at 37 degC by well diffusion method,Other,26048810.0,
2336,1237443,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Micrococcus luteus MTCC 2470 incubated for 24 hrs at 37 degC by well diffusion method,Other,26048810.0,
2337,1237444,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis MTCC 121 incubated for 24 hrs at 37 degC by well diffusion method,Other,26048810.0,
2338,1237445,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Escherichia coli MTCC 739 incubated for 24 hrs at 37 degC by well diffusion method,Other,26048810.0,
2339,1237446,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Klebsiella planticola MTCC 530 incubated for 24 hrs at 37 degC by well diffusion method,Other,26048810.0,
2340,1237447,1,1,,103171942,4189,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa MTCC 2453 incubated for 24 hrs at 37 degC by well diffusion method,Other,26048810.0,
2341,1237448,1,1,,103171942,4189,Active,,,,,Antimicrobial activity against Candida albicans MTCC 3017 incubated for 24 hrs at 30 degC by well diffusion method,Other,26048810.0,
2342,1257330,1,1,,103171942,4189,Unspecified,116412.0,24239.0,3.0,IC50,Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in rat myocyte,Confirmatory,,
2343,1259252,1,1,,174007377,4189,Active,169655958.0,,26.3506,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
2344,1259253,1,1,,174007377,4189,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
2345,1259255,1,1,,174007377,4189,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
2346,1259256,1,1,,174007377,4189,Active,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
2347,1259309,1,1,,178127377,4189,Active,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
2348,1259310,1,1,,332876868,4189,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
2349,1259311,1,1,,178127377,4189,Active,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
2350,1259313,1,1,,85148356,4189,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
2351,1259318,1,1,,85148356,4189,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
2352,1259325,1,2,,336956223,4189,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
2353,1259344,1,1,,144204152,4189,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2354,1259355,1,1,,11112680,4189,Inconclusive,,,0.0018,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
2355,1259356,1,1,,11112680,4189,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
2356,1259409,1,1,,363905874,4189,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
2357,1259415,1,1,,85148356,4189,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
2358,1259416,1,2,,340080254,4189,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2359,1259421,1,1,,340080254,4189,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2360,1259423,1,2,,354807788,4189,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2361,1259423,1,2,,354919114,4189,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2362,1259423,1,2,,354930538,4189,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2363,1259423,1,2,,354939132,4189,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
